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Background Biochemical abnormalities associated with micronutrient status and 
non-alcoholic fatty liver disease (NAFLD) are often observed prior to bariatric 
surgeries, and the changes following surgery can be associated with either 
improvements or worsening. However, evidence on these changes following 
laparoscopic sleeve gastrectomy (LSG) is limited.  
Purpose The purpose of this quasi-experimental study was to determine the 
baseline status of certain biochemical parameters associated with micronutrient 
status and NAFLD prior to LSG and compare them to the status post-LSG.  
Methods A total of 188 patients, who underwent the LSG procedure between May 
2011 and May 2014, consented to partake in this study. Laboratory measurements 
of select biochemical parameters associated with micronutrients (25-
hydroxyvitamin D, PTH, vitamin B12, calcium, ferritin, hemoglobin and mean cell 
volume) and NAFLD status (bilirubin, ALP, ALT, GGT, HDL, LDL and triglycerides) 
were assessed at baseline and re-evaluated at 3 and 6 months post-LSG.  
Results A subgroup consisting of 95 patients were included in the current thesis, as 
they had completed their baseline, 3 and 6 months evaluations. 82.1 % of patients 
were female with a mean BMI of 49.3 ± 6.8 kg/m2. At baseline, 53 patients (55.8 %) 
presented with abnormal blood levels for the micronutrient-related parameters, and 
there was a non-significant decrease to 50.5 % and 46.3 % at 3 and 6 months post-
LSG, respectively. Prior to surgery, the most common abnormalities were elevated 
PTH and low 25-hydroxyvitamin D (25-OH-D). The majority of the micronutrients 
and related parameters did not change significantly following LSG. A significant 
reduction in the proportion of patients with low 25-OH-D was observed, from 21.3 
% at baseline to 1.4 % (1 patient) at the 6-month follow-up (p < 0.001), which may 
be attributed to increased supplement use. The majority of patients (80 %) 
presented with abnormal blood levels for one or more of the select parameters 
associated with NAFLD at baseline, the most common being abnormal GGT, 
triglycerides, HDL, LDL and ALT. There was a significant improvement post-
operatively, with 60 % and 50.5 % of patients at 3 and 6 months post-LSG, 
respectively, presenting with abnormal levels for the select biochemical parameters 
(p < 0.001).  
Conclusion Patients experienced an improvement in 25-OH-D post-LSG, which may 
have been attributed to increased use of supplements. An improvement in the 
majority of the biochemical parameters associated with NAFLD was also observed. 
The overall improvements observed may also be attributed to the significant weight 
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1.1. Background and Rationale 
There is an increasing worldwide obesity epidemic occurring, and there have 
never been as many overweight and obese individuals as there are today (Kazaks & 
Stern, 2013). While overweight and obesity used to be mainly an issue in Western 
countries, it is now a global problem, with increasing obesity rates occurring in most 
countries. Obesity is associated with multiple comorbidities, and today, the majority 
of the population live in countries where more people die due to overweight and 
obesity, than underweight [World Health Organization (WHO), 2013]. The 
increasing incidence rates places a burden on the global health care systems, due to 
increased visits to health professionals, hospital admissions, etc. (Kazaks & Stern, 
2013; Twells et al., 2012).  
There are several different treatment options for overweight and obese 
individuals, some more effective than others. Weight loss is best achieved through a 
combination of proper diet and an effective exercises routine. Exercise on its own is 
not enough, if there are no changes made to food intake (Kazaks & Stern, 2013; Lau 
et al., 2007). The majority of people trying to lose weight will attempt to make 
lifestyle changes, such as trying new diets and/or exercise routines, pharmacological 
agents or commercial weight loss programs (Kazaks & Stern, 2013; Lau et al., 2007). 
Every other year, there is a new diet promising to be the solution to overweight and 
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obesity. Some of these are the Atkins diet, soup diet, 5-2 diet (fasting two days of the 
week), the South Beach diet and the currently very popular Paleo diet (Everyday 
Diet, 2014). Even though these interventions might help some individuals, they often 
don’t result in permanent weight loss for the majority of individuals living with 
overweight and obesity. An estimated 60 % of people who have lost weight due to 
either exercise, diet or both, will regain most of the weight they have lost within a 
year (Sharma & Padwal, 2009). Some of the more effective solutions are commercial 
weight loss programs, such as Weight Watchers and Jenny Craig. Through these 
types of programs, people often receive counseling or guidance in addition to being 
part of a group, resulting in weight loss of up to 10 % after the first year. The 
programs however are not a permanent solution, and people must adhere to the 
restrictions of the program to maintain the weight loss (Jenny Craig, n.d.; Weight 
Watchers, n.d.).  
 
For the severely obese who have exhausted all lifestyle and medical weight 
loss options, bariatric surgery is the only solution resulting in significant reduction 
of weight and improvement or resolution of obesity-associated comorbidities 
(Kazaks & Stern, 2013). Bariatric surgeries available to obese patients are often 
classified as either restrictive or mal-absorptive (Salzman & Karl, 2013). The gold 
standard of bariatric surgeries is the Roux-en-Y gastric bypass (Shankar et al., 2010). 
In this restrictive and mal-absorptive procedure, a portion of the gastric pouch is 
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removed, and a section of the small intestine is bypassed. According to the 2011 
Metabolic/Bariatric Surgery Worldwide report, the most commonly performed 
procedure is the Roux-en Y gastric bypass, 46.6 %, followed by the laparoscopic 
sleeve gastrectomy (LSG), 27.8 % and gastric banding, 17.8 % (Buchwald & Oien, 
2013).  
The relatively new procedure, the LSG, is becoming increasingly more 
popular, and now contributes to almost 30 % of all bariatric procedures (Buchwald 
& Oien, 2013). It is primarily a restrictive procedure, where the patient will have a 
large portion of the gastric pouch removed, leaving a much smaller tube, or sleeve 
(Roa et al., 2006; van Rutte et al., 2012). This surgery was initially performed as the 
first of a two-step procedure, where severely obese patients would undergo LSG in 
order to lose weight, before undergoing gastric bypass or biliopancreatic diversion 
[American Society for Metabolic and Bariatric Surgery (ASMBS), 2012; van Rutte et 
al., 2012; Snyder-Marlow et al., 2010]. However, the weight loss and 
improvement/resolution of comorbid conditions was significant with LSG on its 
own, and comparable to other bariatric procedures, which led to the procedure 
becoming its own independent surgery and was done as a stand-alone procedure for 
the first time in 2004 (ASMBS, 2012; Paluszkiewicz et al., 2012; Peterli et al., 2013). 
By 2011, LSG was the second most common bariatric procedure performed 
worldwide, with 94,689 surgeries done in that year alone (Buchwald & Oien, 2013). 
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1.2. Problem Statement 
Studies have shown that many bariatric patients present with biochemical 
abnormalities prior to undergoing surgery. In addition, the changes observed for 
these parameters in the post-operative period can be associated with 
improvements, but also with worsening of certain pre-existing conditions (Koch & 
Finelli, 2010; Lovette et al., 2012; Salzman & Karl, 2013; Kopec & Burns, 2011, 
Mahaling et al., 2013; Paschos & Paletas, 2009; Hafeez & Ahmed, 2013).  
 
Some of these biochemical parameters are associated with micronutrient 
status, and the proportion of micronutrient-related abnormalities might change 
following surgery, but there are some discrepancies as to if this change is a decrease 
or an increase (Aasheim et al., 2012; Coupaye et al., 2009). It is therefore important 
to assess individuals for micronutrient abnormalities prior to undergoing surgery, in 
order to treat any pre-existing abnormality (Aarts et al., 2012). According to the 
2013 Clinical Practice Guidelines for bariatric surgery, the specific micronutrient 
parameters measured, varies depending on the type of surgery. For the mal-
absorptive procedures, a more extended panel of parameters is advised post-
operatively than is advised for the restrictive procedures (Mechanick et al., 2013).  
Since LSG is considered a primarily restrictive procedure by not bypassing 
the intestine it is expected to only have a minimal influence on the micronutrient 
status. (Capoccia et al., 2012; Leivonen et al., 2011; Moize et al., 2012) However, 
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some studies have shown a change in micronutrient (vitamins and minerals) status 
following surgery suggesting the procedure may be mal-absorptive and restrictive, 
although there is not a general consensus of the direction of change (Aarts et al., 
2011; Damms-Machado et al., 2012; Gehrer et al., 2010; Kehagias et al., 2011). The 
main purpose of this study is to determine baseline micronutrient status of select 
biochemical parameters in patients undergoing LSG, and compare it the short-term 
outcomes at 3 and 6 months following surgery in order to determine a possible 
change.  
 
It is purported that one of the major causes of obesity is poor diet quality. A 
high intake of food that is high in calories and carbohydrates, but low in essential 
micronutrients, is often the most convenient and affordable (Lovette et al., 2012). 
This excess of food, but lack of nutrients, cannot only lead to overweight and obesity, 
but several comorbid conditions. Bariatric surgeries are often the only options for 
overweight and obese individuals to be healthier, as they are associated with 
significant weight loss and an improvement and/or resolution of certain co-
morbidities (Kazaks & Stern, 2012; Snyder-Marlow et al., 2010). One of the major 
conditions associated with obesity is metabolic syndrome, which covers several 
comorbidities such as hypertension, dyslipidemia and diabetes.  
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The hepatic manifestation of the metabolic syndrome is a liver condition 
known as non-alcoholic fatty liver disease. Studies have shown that a large portion 
of the overweight and obese populations suffers from this condition (Franzini et al., 
2011; Mishra & Younossi et al., 2012; Razavizade et al., 2012; Shifflet & Wu, 2009). It 
has been suggested that bariatric surgery might improve this condition as well and 
thus lead to improvements in the biochemical parameters associated with this 
condition. However, the majority of studies conducted on this topic have focused on 
the Roux-en-Y gastric bypass, gastric banding or biliopancreatic diversion (Pillai & 
Rinella, 2009; Hafeez & Ahmed, 2013). To date, there are only two identified 
published studies that examine the possible improvement of this liver condition 
following laparoscopic sleeve gastrectomy (Karcs et al., 2012; Mattar et al., 2005). 
Therefore, the secondary focus of this study will be to evaluate select biochemical 







2. Literature Review 
The purpose of the literature review is to review and identify the gaps in the 
current literature available on obesity and biochemical abnormalities following LSG. 
This chapter will cover the epidemiology of overweight and obesity worldwide as 
well as nationally and at the local provincial level, and the bariatric surgery 
treatment options available. The possible causes of biochemical abnormalities 
associated with bariatric surgery will be presented along with the associated 
medical conditions. An initial literature search was conducted using the PubMed, 
EMBASE, and CINAHL databases along with the Cochrane Library (Appendix 2. 1) 
The MeSH terms and keywords used in the search were “sleeve gastrectomy, 
bariatric surgery, gastric bypass, gastric banding” in combination with one or more 
of the following: “micronutrient/s, vitamin/s, deficiency/deficiencies, NAFLD or 
NASH”. The search resulted in 17 relevant articles on sleeve gastrectomy and 58 
articles on bariatric surgery. Manual searches of references list from potentially 
relevant papers was performed in order to identify additional studies that may have 
been missed using the computer-assisted search strategy. 
 
2.1. Obesity 
The World Health Organization (WHO) defines obesity as: “abnormal or 
excessive fat accumulation that may impair health” (WHO, 2013). Overweight and 
obesity is most commonly classified according to an individual’s body mass index 
(BMI), which is defined as weight in kilograms divided by height in meters squared, 
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or kg/m2 (Table 2.1). The BMI is also used to define the population eligible for 
bariatric surgery. According to the Canadian Clinical Practice Guidelines, patients 
undergoing bariatric surgery must have a BMI > 40 kg/m2 or a BMI ≥ 35 kg/m2 plus 
risk factors (Lau et al.; 2007). 
 
Table 2. 1  
BMI classifications and risk factors.  
BMI (kg/m2) Classification Risk of comorbidities 
< 18.5 Underweight Increased 
18.5 – 24.9 Normal weight Minimal 
25.0 – 29.9 Overweight Increased 
30.0 – 34.9 Obese I High 
35.0 – 39.9 Obese II Very high 
> 40.0 Obese III Extremely high 
Note: From Statistics Canada (a).  
 
2.1.1. Causes of obesity 
The causes of overweight and obesity are complicated, as there are numerous 
factors that contribute to the risk of development. The simplest explanation is that 
more calories are ingested compared to the amount of calories expended (Kazaks & 
Stern, 2013). The causes of overweight and obesity are often multifactorial; genetics, 
social-economics, cultural and environmental influences can play a significant role 
(Katzmarzyk & Mason, 2006; Lau et al., 2007; Sharma & Padwal, 2009).   
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2.1.2. Co-morbidities and risk of mortality 
Overweight and obesity are associated with many comorbidities. Some of the 
main comorbidities related to overweight and obesity are diabetes, cardiovascular 
disease, sleep apnea, osteoarthritis, non-alcoholic fatty liver disease and certain 
cancers (Lau et al., 2007; Navaneelan & Janz, 2014). As BMI increases, so does the 
risk for developing these conditions (WHO, 2013). The risk of developing health 
problems is lowest when an individual is within the normal BMI range. The risks 
associated with BMI are often described by a J or U curve, with increasing risk of 
mortality seen at either end (Figure 2.1). There is a very low health risk for 
individuals with a normal weight, however, when the BMI values are within the 
three obesity classes, the health risk increases further (Twells, 2005; WHO, 2013).  
 
 
Figure 2. 1. Mortality curve of BMI classes. 
Note: Used with permission from Gray, D. S. (1989) Diagnosis and Prevalence of 
Obesity. Medical Clinics of North America. Volume 73, issue. 1. 
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2.2. Epidemiology of obesity  
The incidence rate of overweight and obesity is increasing worldwide, with 
more than 1.4 billion adult being overweight (WHO, 2014). People categorized as 
overweight or obese outnumber people with a normal weight, and the majority of 
the world’s population now live in countries where more people die of overweight 
and obesity related causes than underweight (Kazaks & Stern, 2013; Lau et al., 
2007). Even though the incidence is not increasing as much as in previous years, and 
may even have levelled off in some countries, the overweight and obesity rates 
remain high [Kazaks & Stern; 2013; Organisation for Economic Co-operation and 
Development (OECD), 2012]. The obesity epidemic is more prevalent in Western 
countries, with North and South America having the highest prevalence (62 % 
overweight and 26 % obese). The lowest prevalence is found among the Asian 
countries (Figure 2.2), with only 14 % overweight and 3 % obese (WHO, 2014). 
According to the 2012 Obesity Update from the Organisation for Economic Co-
operation and Development (OECD), the overweight and obesity rates have been 
stable in Korea, Switzerland, Italy, England and Hungary over the past couple of 
years; however the rates are not decreasing (OECD, 2012). Although the epidemic 
used to be more prevalent in the developed countries, the rates are increasing in the 






Figure 2. 2 Global obesity rates.  






Canada is among the countries with the highest overweight and obesity rates 
and is following the global pattern with increased prevalence rates. According to a 
recently published study, the prevalence of obesity among the adult Canadian 
population in 2011-2012 was 24.8 %, which was a 17.5 % increase from 2003 
(Navaneelan & Janz, 2014). In addition to this, the 2009-2011 Canadian Health 
Measures Survey (CHMS) Cycle 2 showed that 16.2 % of Canadians between 18 – 70 
years of age were in the obese class I, 6.3 % were in the obese class II and 3.7 % 
were in the obese class III [Statistics Canada (b), 2013]. 
 According to the 2011 Obesity in Canada report, the cost of overweight and 
obesity was about $4.6 billion in 2008, which was a 19 % increase from 2000. This 
estimate was done by including a number of chronic diseases associated with 
overweight and obesity, but the actual cost may be even higher if all related 
conditions are included [Public Health Agency of Canada (PHAC), 2011]. 
 
2.2.2. Newfoundland and Labrador 
Newfoundland & Labrador has consistently been among the provinces with 
the highest rates of adult overweight and obesity, and the increase in prevalence 
rates occur at a much higher rate there than in other provinces. The rates are similar 
among other Atlantic Provinces; Prince Edward Island, Nova Scotia and New 
Brunswick along with the Northwest Territories [Human Resources and Skills 
Development Canada (HRSDC), 2014; Navaneelan & Janz, 2014; Twells et al., 2014].  
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In 2011-2012, the prevalence of obesity was second highest in this province, 
with 35.2 % of the population being considered as obese, only the Northwest 
Territories had a higher prevalence (35.3 %) than Newfoundland & Labrador 
(Navaneelan & Janz, 2014). If the current increasing trend continuous, it is estimated 
that more than 70 % of the Newfoundland & Labrador population will be 
overweight or obese in 2019 (Twells et al., 2014). Among the obese population in 
Newfoundland & Labrador, there is a significantly higher prevalence of visits to 
private physicians and general practitioners, when compared to the normal weight 
population. The obese population in Newfoundland & Labrador also have 
significantly more chronic conditions than the normal weight population (Twells et 






2.3. Bariatric Surgery 
There are several reports suggesting that obesity is associated with an 
increased risk of mortality due to the numerous obesity related conditions (Adams 
et al., 2007; Pontiroli & Morabito, 2011; Sjostrom et al., 2007; Walker et al., 1995). In 
addition, studies have shown that a significant weight loss improves many of these 
conditions, suggesting that weight loss might lead to a reduction of the mortality risk 
(Sjostrom et al., 2007; Sjostrom et al., 2012; Torgersen et al., 2014; Williamson et al., 
1995). However, there continues to be conflicting reports as to whether weight loss 
is actually associated with the risk of overall mortality, and there is limited literature 
available (Adams et al., 2007; Pamuk et al., 1993; Sjostrom et al., 2012; Williamson 
et al., 2000).  
While some studies are reporting that weight loss is associated with a 
reduction in overall mortality (Pamuk et al., 1993; Williamson et al., 1995; 
Williamson et al., 2000), the majority are reporting increased mortality being 
associated with weight loss (Pamuk et al., 1993; Walker et al., 1995; Wannamethee 
et al., 2000; Williamson et al., 1995). A limitation to these studies though, is the fact 
that they fail to distinguish between intentional weight loss and unintentional 
weight loss that might be a consequence of a condition leading to death, not the 
cause of it (Pamuk et al., 1993; Sjostrom et al., 2007; Walker et al., 1995; Williamson 
et al., 1995). 
 
15  
Many studies have reported that bariatric surgery is associated with a 
reduced risk of mortality, not the weight loss itself (Adams et al., 2007; Christau et 
al., 2004; Pontiroli & Morabito, 2001; Sjostrom et al., 2007; Sjostrom et al., 2012). In 
the Swedish Obesity Subjects study, undergoing bariatric surgery (gastric bypass) 
was associated with a 40 % reduction of all cause mortality, as well as a reduced risk 
of cardiovascular death, fatal myocardial infarction and stroke (Sjostrom et al., 2007; 
Sjostrom et al., 2012). The fact that bariatric surgery is associated with a reduced 
risk of mortality could suggest that it might be due to the weight loss. However, it 
might also be because bariatric patients are followed more closely by their health 
care professional, thus providing health care above the normal standard of care that 
their “control” would receive (Sjostrom et al., 2007). There continues to be a great 
need for studies assessing the association between intentional weight loss and the 
risk of mortality. In the end, a reduced risk of mortality following bariatric surgery is 
more important than the weight loss itself.  
Bariatric surgery has been deemed the best treatment option available to the 
obese population in order to obtain and sustain significant weight loss. Patients tend 
to lose an estimated 20 -40 % of their initial body weight after bariatric surgery, 
which is the equivalent to an estimated BMI loss of 14 kg/m2 (Salzman & Karl, 2013, 
Torgersen et al., 2014).  Bariatric surgeries are usually classified into one of two 
categories; mal-absorptive or restrictive. Mal-absorptive procedures involve an 
anatomical alteration, usually a bypass of the intestines. By bypassing a section of 
the small intestine, the amount of absorption from the diet is limited, as much of the 
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micronutrient absorption takes place in the small intestine (Valentino et al., 2011). A 
restrictive procedure however, involves either a temporary or permanent reduction 
in the size of the gastric pouch. This reduction in stomach size reduces the amount of 
food that can be consumed, and may also have an effect on the absorption. Many of 
the enzymes and co-factors for micronutrient absorptions are produced in the 
gastric pouch (Salzman & Karl, 2013; Snyder-Marlow et al., 2010; Valentino et al., 
2011).  
 
2.3.1. Roux-en Y Gastric Bypass (RYGB) 
The Roux-en Y gastric bypass is the most common bariatric procedure in 
North America, and is considered the gold standard of bariatric surgeries (Malone, 
2009; Shankar et al., 2010). It can be performed as an open surgery but most are 
done as a laparoscopic Roux-en Y gastric bypass (LRYGB).  
RYGB is considered to be a combined restrictive and mal-absorptive 
procedure (Pillai & Rinella, 2009). The majority of the gastric pouch is resected and 
removed from the body, leaving only a small pouch in addition to the first portion of 
the small intestine being bypassed (Figure 2.3). Due to the small stomach size, 
patients will lose weight rapidly post-surgery due to a significant reduction in food 
intake (Koch & Finelli, 2010; Malone, 2009). It is the type of bariatric surgery 
associated with the greatest weight loss, making it very desirable (Lassailly et al., 
2013; Mattar et al., 2005).  
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2.3.2. Adjustable Gastric Banding (AGB) 
This type of procedure is more common in Europe than in North America, 
and is attractive due to the fact that it is reversible. However, there has been a 
worldwide decline in the use of this procedure over the years, decreasing from 
145,563 procedures performed in 2008, to just 60,677 procedures in 2011 
(Buchwald & Oin, 2013).  
A band is placed around the stomach to create a smaller pouch at the site 
where food first enters the stomach (Malone, 2009). The band is adjustable through 
a subcutaneous port just above the abdominal muscles (Figure 2.4), meaning the 
size can be adjusted for certain occasions (Gasteyger et al., 2006).  
 
2.3.3. Laparoscopic Sleeve Gastrectomy (LSG) 
This relatively new surgical procedure was initially performed as a first step 
in a two-step operation for patients with high BMIs or increased risk of surgical 
complications (Roa et al., 2006). Patients would undergo LSG, followed by 
biliopancreatic diversion (BPD) or duodenal switch (DS). However, studies found 
that the weight loss after the first step was significant, and LSG became a stand-
alone procedure (ASMBS, 2012; van Rutte et al., 2012; Snyder-Marlow et al., 2010). 
Studies have shown that the weight loss and improvement of co-morbidities is 
similar to that of the RYGB within the first year after surgery, with the exception of 
gastroesophageal reflux disease and the remission of type 2 diabetes, and in 2012, 
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the sleeve gastrectomy was recommended as an alternative to RYGB by the 
American Society for Metabolic and Bariatric Surgery. (Torgersen et al., 2014; Peterli 
et al., 2013) 
Between 60 and 85 % of the stomach is removed, leaving a small “sleeve-like” 
pouch (Figure 2.5). The procedure is done laparoscopically using 5 or 6 trocars, and 
the size of the new stomach pouch is determined by a French bougie. The size of 
bougie varies among studies (e.g., 32 to 60), leaving the volume of the stomach 
between 75 – 120 mL (van Rutte et al., 2012). It is debated whether this procedure is 
purely restrictive, as there is an irreversible anatomical alteration of the stomach 




Figure 2. 3 
Roux-en Y gastric bypass 
Note: Used with permission from 





Figure 2. 4 
Adjustable gastric banding 
Note: Used with permission from 





Figure 2. 5 
Laparoscopic sleeve gastrectomy 
Note: Used with permission from 
(Padwal et al., 2011)  
20  
2.4. Origins of Micronutrient-related abnormalities 
Micronutrients are essential in the functioning of the human body. They play 
a large role in metabolic processes and are factors of important cellular pathways 
and mechanisms. When the levels of these are either abnormally high or low, the 
consequences can be of serious concern. The origins of micronutrient abnormalities 
have several different causes. Micronutrient-related abnormalities can occur in the 
obese population prior to undergoing surgery, most often due to poor diet. Patients 
can also develop abnormalities following bariatric surgery, which may be related to 
a number of factors including reduction in the amount and quality of food consumed, 
altered digestion and/or absorption, non-adherence to diet regimens and 
recommended supplementation (Salzman & Karl, 2006), and any pre-existing 
abnormalities can improve or worsen following post-surgery as well (Lovette et al., 
2012). 
 
It is important to define the difference between clinical and biochemical 
abnormalities. A clinical abnormality is when an individual shows the symptoms 
associated with the specific deficit of a micronutrient and these can be psychological 
or physiological (Lovette et al. 2012; Salzman & Karl, 2013.) A biochemical 
abnormality is when the specific micronutrient is at a blood level below or above the 
normal reference range. As micronutrient-related abnormalities can be present both 
clinically and biochemically, a patient will usually consult with their primary care 
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physician when certain symptoms are present. If the doctor associates these 
symptoms with specific micronutrients, they will order tests to determine the blood 
levels of these parameters. It is the results from these tests that determine if the 
clinical symptoms are due to a micronutrient abnormality (Blake, 2012). However, 
many of the biochemical abnormalities are discovered incidentally through routine 
blood work, where patients might not be presenting with any symptoms.  
 
2.4.1 Pre-operative 
There are several possible causes of micronutrient-related abnormalities 
among individuals wanting bariatric surgery, the most common being poor diet 
(Salzman & Karl, 2013). The majority of overweight and obese individuals do not get 
the amounts of essential minerals and vitamins required to maintain proper levels in 
their body. There has been a significant increase in the amount of food people eat 
each year, but this increase is not in fruits and vegetables (Kazaks & Stern, 2013; 
Rickers & McSherry, 2012). The intake of food containing high-calories, 
carbohydrates and fat has increased among all gender and races. The poor diet is in 
many cases a reflection of the social-economic or cultural status, since nutritious and 
vitamin-rich foods are often more expensive than the processed, high-calorie 
options. Low-income households, which are at higher risk of being overweight or 
obese, may not focus as much on the quality of food, but more on the quantity 
(Lovette et al., 2012; PHAC, 2011; Sharma & Padwal, 2009).  
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According to the 2007/2008 National Health and Nutrition Examination 
Survey (NHANES), American adults over the age of 20 years did not meet the 
required intake of fibre, vitamins and minerals. Poor diet is not just common in the 
overweight and obese population, but a problem at a global level for normal weight 
people as well (Lovette et al., 2012).  
One of the most common abnormalities found pre-operatively in the 
overweight and obese population, is low vitamin D (i.e. 25-hydroxyvitamin D). This 
can be due to insufficient vitamin D intake from food, such as oily fish (e.g. salmon, 
mackerel), fish-liver or dairy products, but may also occur from a lack of sun 
exposure. The main source of vitamin D is through sunlight exposure, as vitamin D is 
synthesized in the skin and converted into its active form in the liver. However, in 
some cases the release from the skin to the bloodstream may be mechanically 
altered (Dewey & Heuberger, 2011). Because of the stigmatization many obese 
individuals experience, many spend fewer hours outdoors, thus reducing the 
amount of ultraviolet exposure (Ruiz-Tovar et al., 2012; Swaminathan, 2011). In 
addition, people are generally advised by public health organizations to wear 
sunscreen and clothing to cover skin in order to reduce the risk of skin cancer, but 
this blocks the effect that ultraviolet light usually has in skin, to reduce the 
formation of vitamin D.  However, if patients are exposed to adequate quantities of 
sunlight, the surgical procedure will be irrelevant and should not have an effect on 
the blood levels of 25-hydroxyvitamin D.  
23  
2.4.2. Post-operatively 
Many studies have shown an increase in micronutrient-related abnormalities 
following bariatric surgeries, the causes of which may be complex. Some of the 
reasons identified by Saltzman & Karl (2013) were: reduced hydrochloric secretion 
from the gastric pouch, reduced intrinsic factor secretion from the gastric pouch, 
reduced absorption due to anatomical alterations and bacterial overgrowth in the 
small intestine. 
Following most bariatric surgeries, there is a significant reduction in food 
intake, thus less nutrients are available to be absorbed. Even though most 
overweight and obese individuals do not have the most nutrient-rich diet pre-
surgery, they might potentially ingest fewer nutrients afterwards (Aasheim et al., 
2009; Salzman & Karl, 2013). Because diet following bariatric surgery is very 
restrictive, patients are not able to eat otherwise nutrient-rich foods (Rickers & 
McSherry, 2012). One of the hardest things for people to eat following bariatric 
surgery is red meat; however this food item contains important nutrients that the 
human body needs, such as iron, calcium, protein and several vitamins that one must 
now get from other sources (Salzman & Karl, 2013; Swaminathan, 2011).  
Another explanation for the decrease of specific micronutrients is the 
reduced absorption that might take place post-operatively. In the mal-absorptive 
procedures, a part of the small intestine is bypassed. Since this is the main site of 
absorption, it can lead to possible low levels of certain micronutrient-related 
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parameters. In the LSG procedure, the majority of the gastric pouch is removed; 
however, important enzymes and co-factors for nutrient absorption are produced 
and secreted here. Either of these, or a combination, can potentially lead to 
micronutrient-related mal-absorption (Moize et al., 2012; Valentino et al., 2011).  
Obese patients are at risk of developing these abnormalities and as such, the 
ASMBS recommend patients take a vitamin and mineral supplement routinely and 
immediately after surgery (Blume et al., 2012). However, the alteration of the gastric 
pouch and intestinal tract can potentially also contributing to impaired absorption 
of these supplements. This might be the explanation for the minimal effect of 
supplementation reported in some studies. These studies suggest that patients must 
take more than the required daily allowance of specific supplements in order to 
properly treat or prevent a deficiency (Aarts et al., 2012; Blume et al., 2012; 
Dalcanale et al., 2010). 
It has been suggested that bacterial overgrowth of the gastric pouch and 
small intestine can have an effect on vitamin B1, B12 and folate (Koch & Finelli, 2010; 
Lovette et al., 2012; Swaminathan et al., 2011). The mechanisms for this are not fully 
understood, but upper gut bacterial overgrowth has been observed after RYGB and 
AGB. Some studies indicate that the bacteria might ingest vitamin B12, thus making a 
less amounts available for absorption and potentially causing a deficiency 
(Swaminathan, 2011). The effects of bacterial overgrowth can be present before and 
after bariatric surgery (Koch & Finelli, 2010; Lovette et al., 2012).  
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2.5. Current literature on micronutrient changes following bariatric surgery 
Differences among the studies focused on micronutrient-related changes 
following bariatric surgery include varied patient populations, different follow-up 
time points, types of bariatric procedures, supplementation and micronutrient-
related parameters measured (Toh et al., 2009). Because there are inconsistencies 
among the micronutrients studied, some of these variables have only been studied 
once for one surgical procedure, thus making it difficult to draw any overall 
conclusion to the changes following all bariatric procedures.  
 
Despite the fact that micronutrient-related changes following bariatric 
surgeries have been studied by many, there are still many uncertainties regarding 
the direction of these changes from the different procedures (Ziegler et al., 2009). 
While the prevalence of some micronutrient-related abnormalities have been 
reported to increase in some studies (Coupaye et al., 2009; Toh et al., 2009), the 
same parameters have been observed to decrease or remain stable in others 





2.5.1. Bariatric surgeries and micronutrient abnormalities  
Micronutrient-related abnormalities are common and somewhat expected 
following mal-absorptive procedures, due to the alteration of the gastric pouch and 
the intestinal tract. LSG is typically associated with fewer micronutrient-related 
abnormalities than the mal-absorptive procedures, such as the RYGB (Gehrer et al., 
2010; Salzman & Karl, 2013; Valentino et al., 2011). Some studies measure the 
micronutrient-related parameters at baseline and several times following the 
surgery, thus providing an estimated change over time. Other studies however, only 
present the baseline and the outcomes at one specific follow-up, e.g. at 6 or 12 
months post-operative, or they might only show the results from the follow-up 
period.  
While the changes following gastric bypass surgeries have been studied the 
most, there are few studies examining the micronutrient-related changes that follow 
LSG (Coupaye et al., 2009; Moize et al., 2012). The overall changes in select 
micronutrients following various bariatric procedures are presented in Table 2.2. 
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Table 2.2 
Overall change in laboratory values following bariatric surgery. 
 RYGB GB LSG DS/BPD 
Calcium ? - Increasing/? Decreasing 
Ferritin Decreasing Increasing/? ? N/A 
Hemoglobin Decreasing - ? N/A 
MCV ? ? ? N/A 
PTH Decreasing Decreasing Decreasing N/A 
Vitamin B12 Decreasing -/Increasing ? Decreasing 
25-OH-D Increasing ? Increasing Decreasing 
 
Note: Estimates on changes based on current literature available. ? = Changes not clear from current literature, 
fluctuating levels post-surgery. N/A = Information not available from current literature. - = Stable levels, no change in 
levels post-surgery. (Aarts et al., 2012; Aasheim et al., 2012; Blume et al., 2012; Dalcanale et al., 2010; Gasteyger et al., 
2006; Kehagias et al., 2011; Coupaye et al., 2009; Rickers & McSherry, 2012; Rojas et al., 2011; Toh et al., 2009; Schouten 
et al., 2010; Ziegler et al., 2009) 
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2.5.2. Laparoscopic Sleeve Gastrectomy and micronutrient-related 
abnormalities 
In the literature search on this topic, a total of 11 studies examining changes 
in micronutrient and related parameters following LSG were identified. In all of the 
studies, the authors investigated micronutrient-related deficiencies; however, none 
of studies examined the clinical symptoms that would manifest for any of the 
parameters measured. It is important to note that whenever the authors used the 
term  “deficiency”, it meant the biochemical blood level of a specific micronutrient 
was lower than the normal range.  
As with all the studies on this topic, a micronutrient-related deficiency is 
usually not diagnosed on the biochemical levels alone, but are be made in 
conjunction with corresponding clinical symptoms as well. The 11 studies identified 
on this topic measured a variety of micronutrients-related parameters. The 
following section describes the changes following LSG according to the 11 studies 
(Table 2.3). 
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Table 2. 3  
Summary of the studies on micronutrient-related changes and abnormalities following LSG. 
Study/Country Purpose Design Variables Findings Notes 







iron indices pre- 
and post-LSG. 
Prospective study. 
61 patients, mean 
BMI: 47.5 ± 9.6 
kg/m2.  
Hemoglobin, 
MCV, ferritin and 
vitamin B12. 
Significant decrease 
in ferritin and 




have a majority 













60 patients, mean 






PTH and vitamin 
B12. 
Deficiencies at 12 
months: Vitamin B12 
(9%). 












to surgery, and 
compare the 




136 patients (50 
LSG vs. 86 LRYGB). 
Mean BMI: 46.5 





calcium and PTH. 
Pre-surgery: 57 % 
with at least one 
abnormality, 23 % 
25-OH-D deficiency 
and 8 % elevated 
PTH. 





prior to surgery.  
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OH-D and 18 % 
vitamin B12 
deficiency, 14 % 
elevated PTH. 
Post-LRYGB: 58 % 
vitamin B12, 52 25-















60 patients (30 LSG 
and 30 LRYGB), 
mean BMI: 44.9 




prescribed for all 
LRYGB patients, 
only for the first 3 
months for LSG 
Hemoglobin, 
ferritin, vitamin 
B12, calcium and 
PTH. 
Results for baseline 
and 3 year presen-
ted. No significant 
difference between 
surgery groups, 
except for vitamin 
B12 (more deficien-
cies for LRYGB).  
LSG: 19 abnorma-
lities pre-LSG (iron 
most common), 20 
abnormalities post-
LSG (hemoglobin, 
Follow-up at 1, 
3, 6, 12, 24 and 
36 months post-
surgery, but only 









Study/Country Purpose Design Variables Findings Notes 





mon), 26 post- 
LRYGB (vitamin B12 
most common). 
 










(< 59 years) 
following LSG. 
Prospective study. 
55 patients. 49.5 ± 








vitamin B12 and 
calcium. 
There was no sig. 
difference between 
age groups. 89% of 
older and 48% of 
younger patients 
had an abnormality 
at 12 months. 25-
OH-D deficiency 
being most 
common. All mean 




Only 12 patients 
> 59 years of 
age. 
D. Capoccia et al. 
2012 
Italy 
Analyze the role 
of weight loss on 
micronutrient 
abnormality 
Prospective study.  
138 patients, mean 








line to 12 months 
follow-up. No signi-
No elaboration 
of the low 
vitamin D levels.  
No data analyses 
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Study/Country Purpose Design Variables Findings Notes 
development. Divided in 5 BMI 
groups.  
Uniform 
supplements to all 
patients for the 





within normal range 
pre- and post-LSG, 
except vitamin D.  
techniques 
provided in the 
methods section.  
A. Damms-








study. 54 patients, 
mean BMI: 51.0 ± 




B12 and calcium. 
51 % had at least 
one deficiency pre-
LSG, most common 
being 25-OH-D (83 
%). Decreasing 

















between LSG and 
RYGB patients. 
Prospective study. 
355 patients, mean 









OH-D and PTH 
No difference in 
dietary intake 
between groups.  
Low 25-OH-D and 
elevated PTH were 
the most common 
abnormalities. Base-
line abnormalities 











Study/Country Purpose Design Variables Findings Notes 
similar among 
procedure-groups.  







30 female patients, 
mean BMI: 53.1 ± 
8.5 kg/m2.  
Uniform 
supplements 




D, PTH and 
vitamin B12.  
Pre-LSG 
abnormalities: 
vitamin D (96.7 %), 
PTH (20 %).           
12 months 
abnormalities: 
vitamin D (3.3 %) 




weight loss and 
vitamin D increase 
(r = -0.948, p = 
0.033). 
No mentioning 





T. Saif et al.  
2012 
United States 
To evaluate the 
micronutrient 
status in patients 
undergoing LSG 
Prospective study.  
82 patients, mean 
BMI: 55.7 ± 13.7 
kg/m2.  






B12 and vitamin D. 
Most common 
abnormalities pre-
LSG: Vitamin D (75 
%) and PTH (51.5 
%). Increasing 
levels: Ferritin (F) 
and vitamin D. 
Large drop-out 
rate, > 50 % at 
each follow-up.  
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Study/Country Purpose Design Variables Findings Notes 
Decreasing levels: 
Ferritin (M) and 
PTH. Stable levels: 
Hemoglobin and 
calcium. 










within 12 months 
post-LSG. 
Retrospective 
study. 200 patients, 
mean BMI: 46.2 
kg/m2. Patients 









globin (5%), MCV 
(5.5%), ferritin (7%, 
all female), calcium 
(0.5%), vitamin B12 
(11.5), vitamin D 
(81%), PTH excess 
(28.5%). 
12 months: Hemo-
globin (6.5%), MCV 
(2%), ferritin (8%, 
all female), calcium 
(2%), vitamin B12 
(11.5), vitamin D 




study, only 200 
had completed a 
follow-up visit.  
Note: LSG = Laparoscopic sleeve gastrectomy. BMI = Body Mass Index. 25-OH-D = 25-hydroxyvitamin D. PTH = 
Parathyroid Hormone. MCV = Mean Cell Volume. M = Males, F = Females. 25-OH-D = 25 hydroxyvitamin
35  
Hakeam et al., (2009). Obese patients who underwent LSG at a Saudi Arabian 
hospital were eligible to participate in the study, unless they presented with any 
inflammatory disorders, arthritis, were on steroids, had anemia, chronic infectious 
diseases, hypothyroidism or a pre-existing iron deficiency. Follow-up was at 6 
months, and the laboratory measurements included hemoglobin, MCV, ferritin and 
vitamin B12. All patients were given an iron-free supplement containing vitamin B12 
post-LSG.  
A total of 61 patients participated in the study, 31 of which were male, with a 
mean BMI of 47.5 ± 9.6 kg/m2. The only abnormality found at baseline, was a 
vitamin B12 deficiency in five patients (8.1 %). At 6 months, there were 19 newly 
developed abnormalities, the most common being vitamin B12 deficiency (19.6 %). 
There was no significant change in MCV, hemoglobin and ferritin values, which 
stayed stable throughout the study.  
A possible limitation of the study is the fact that all the patients had normal 
iron and hemoglobin values prior to surgery. Since many obese patients have 
micronutrient abnormalities pre-surgery, these patients might not be representative 
of the obese population in general. In addition, > 50 % of the patients were male, 
which is in contrast to most studies on this topic. This might have an effect on the 
study results, as women, especially those that are pre-menopausal, tend to be more 
at risk for developing low ferritin and hemoglobin levels.  
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E. O. Aarts et al. (2011) The aim of this Dutch prospective study was to assess 
the micronutrient abnormalities following LSG. The patients underwent LSG as a 
first step procedure, before possibly undergoing duodenal switch (DS). Within the 
first year post-LSG, six patients underwent DS and they were excluded from 
participating in the study. Patients were instructed to take a daily multivitamin, but 
it is not clear whether this supplementation was provided or not. The follow-up 
assessment after LSG was at 12 months, and the micronutrient parameters 
measured were hemoglobin, MCV, calcium, PTH and vitamin B12.  
A total of 60 patients enrolled in the study, 34 were males. The only 
micronutrient assessment done on patients prior to surgery was the values of 
hemoglobin and MCV, with 8.3 % having low MCV and 5.0 % having low hemoglobin 
values. At 12 months follow-up, the most common micronutrient abnormalities 
were low concentrations of hemoglobin along with elevated PTH (43 %, 26 % and 
39 %, respectively). In addition, the study reported low MCV and high calcium 
values (15 % and 4 %, respectively) while one patient presented with low vitamin 
B12.  
 
S. Gehrer et al. (2010) The aim of this non-randomized, prospective trial was 
to assess the micronutrient deficiencies prior to surgery, and compare the outcome 
from LSG to those from LRYGB. 136 patients were enrolled in the study, 50 of which 
underwent LSG and 86 underwent LRYGB. Micronutrient assessment follow-up 
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were done at 3, 6, 12, 30 and 36 months, and the micronutrient parameters 
measured were vitamin B12, 25-hydroxyvitamin D, calcium and PTH. Before 
undergoing surgery, 57 % of the patients presented with at least one micronutrient 
abnormality, the most prevalent being 25-OH-D deficiency and elevated PTH, 23 % 
and 8 % respectively. Any deficiency detected was treated accordingly.  
The statistical analysis on the micronutrient changes pre- and post-surgery is 
done on a variable named “post-operative”, which appears to be an overall estimate 
of the results from 3 – 36 months post-surgery. There were significantly more 
deficiencies post-operatively among patients who underwent LRYGB; the most 
common deficiencies were vitamin B12 and 25-OH-D (58 % and 52 %, respectively), 
33 % had elevated PTH levels. For patients in the LSG-group, the most common 
deficiencies after surgery were 25-OH-D, and vitamin B12 32 % and 18 %, 
respectively. PTH was elevated in 14 % of the patients, while no abnormal values for 
calcium were found. There were a significant difference in the number of 
abnormalities between the two surgical groups for vitamin B12, 25-OH-D and PTH. 
The majority of micronutrient abnormalities presented within the first year 
following both LSG and LRYGB. Targeting the specific micronutrient resolved the 
majority of micronutrient abnormalities, and the improvement/resolution rates 
were between 80 – 100 % for vitamin B12, iron and 25-OH-D.  
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I. Kehagias et al. (2011) The aim of this study was to compare the outcomes 
for LSG and LRYGB patients. 60 patients were randomized to receive either LSG (30 
patients) or LRYGB (30 patients) at a hospital in Greece. Only the surgeons 
performing the procedures were aware of the type of surgery the patients had, 
making it a double-blind, randomized trial, as neither the patients, caregivers or the 
individuals collecting data knew the surgery type in question. 
All patients were prescribed a uniform vitamin and mineral supplement; 
however, patients who received the LSG procedure were only prescribed this for the 
first six months post-surgery. In addition, pre-menopausal women in the LRYGB 
group also received an oral iron supplement. Follow-up was done at 1, 3, 6, 12, 24 
and 36 months post-surgery. The parameters measured in the study included 
hemoglobin, ferritin, vitamin B12, calcium and PTH. 
The number of micronutrient abnormalities at baseline was similar for the 
two groups, with iron and hemoglobin deficiencies being the most common. Only the 
results for baseline and 36 months follow-up were presented, and there was an 
increase in the number of abnormalities, 19 to 20 vs. 15 to 26 for LSG and LRYGB 
respectively. The most common abnormalities after surgery were ferritin and 
hemoglobin deficiencies for the LSG group, while vitamin B12 deficiencies were more 
prevalent among the LRYGB patients.  
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Except for vitamin B12, there was no significant difference between the two 
groups in terms of micronutrient abnormalities. The number of abnormalities at 
baseline and 36 months follow-up are somewhat similar, especially for the LSG 
group. Patients in the LRYGB were more at risk for developing micronutrient 
abnormalities after surgery, despite the fact that they received vitamin and mineral 
supplementation for the duration of the study.  
 
M. K. Leivonen et al. (2011) The aim of this prospective study was to compare 
the micronutrient changes in patients over and under 59 years of age, 12 months 
after LSG. A total of 152 patients had the LSG procedure at a hospital in Finland, but 
only 55 patients had been evaluated for the 12 months follow-up at the time the 
article was written. Of these 55 patients, 12 were older than 59 years, and all 
patients were provided a permanent supplement regimen post-surgery. Follow-up 
was done 12 months post-LSG, and the micronutrient parameters measured were 
hemoglobin, MCV, 25-OH-D, vitamin B12 and calcium.  
At the 12-month follow-up, 89 % of the ≥ 59 years patients and 48 % of the 
<59 years patients had at least one micronutrient abnormality. However, all the 
mean blood values were within the normal ranges post-LSG. 25-OH-D deficiency was 
the most common abnormality found, and was more prevalent among the ≥ 59 
patients; 25 % vs. 19 % when compared to patients < 59 years. However, this 
difference was not significant, and the micronutrient abnormalities occurred despite 
40  
multivitamin supplementation. The major limitation to this study is the lack of pre-
LSG measurements. The biochemical values and number of abnormalities at 12 
months are not informative in regards to the effect of LSG on these parameters, as 
there was no baseline assessment conducted.  
 
D. Capoccia et al. (2012) The aim of this Italian study was to analyze the effect 
weight loss had on the development of micronutrient deficiencies, as well as the 
effect of supplementation. A total of 138 patients underwent LSG. They were divided 
into five groups determined by their pre-LSG BMI. Group A: BMI between 32 – 34.9 
kg/m2, 7 patients. Group B: BMI between 35 and 39.9 g/m2, 29 patients. Group C: 
BMI between 40 and 44.9 g/m2, 40 patients. Group D: BMI between 45 and 49.9 
g/m2, 33 patients. Group E: ≥ 50 g/m2, 29 patients.  All patients were provided 
uniform supplementation for the first 6 months. After the first 6 months patients 
received only vitamin B12 and vitamin D. The follow-up assessments were done at 3, 
6 and 12 months; however, only the 12 months data are presented in the article. The 
parameters measured were hemoglobin, vitamin B12, calcium and vitamin D.  
There was no significant change observed in the biochemical parameters 
from baseline to the 12 months follow-up. In addition, there was no significant 
difference among the five BMI groups. All the mean micronutrient values were 
within the normal ranges pre- and post-LSG, except for vitamin D. The authors 
concluded that the supplements provided to the patients proved sufficient to avoid 
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any post-LSG abnormalities, except for vitamin D. The authors state that the vitamin 
D levels were low before and after surgery, but provide no estimate on the 
proportion of patients with low levels. Because the proportion of abnormalities is 
not provided, it is unclear if all patients had sufficient levels of hemoglobin, vitamin 
B12 and calcium, as suggested by the normal mean values.  
 
A. Damms-Machado et al. (2012) The aim of this German observational study 
was to assess micronutrient deficiencies at baseline and at 12 months post-LSG. 
Patients had follow-up assessments done at 3, 6 and 12 months after surgery. 
Patients were advised to take a multivitamin immediately after surgery. The 
micronutrient parameters measured in the study were 25-OH-D, vitamin B12 and 
calcium. 54 patients were enrolled in the trial, and were measured for 25-OH-D and 
vitamin B12. A subgroup consisting of 30 patients were additionally measured for 
calcium.  
Of the 54 patients enrolled in the study, 39 were female (72 %). Prior to 
undergoing surgery, 51 % of the patients presented with at least one micronutrient 
deficiency, the most common being 25-OH-D and iron, (83 % and 29 %, 
respectively). The most commonly occurring abnormality following LSG was 25-OH-
D deficiency. 3 months following LSG, 59.5 % of the patients presented with 25-OH-
D deficiency, 2.4 % had low vitamin B12 levels, while no patients experienced low 
levels of calcium. At the 6-month follow-up, the proportion of patients with 25-OH-D 
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deficiency had increased to 76.2 %, and the prevalence of patients with vitamin B12 
deficiency was 4.8 %.  
The percentage of patients that reported taking some sort of micronutrient 
supplements following LSG were 41 %, 26 % and 22 % at 3, 6 and 12 months, 
respectively, the most common being an over-the-counter multivitamin (69 %). 
There were no significant differences in micronutrient parameters between patients 
taking supplements and those who did not, except for 25-OH-D, where supplement 
use seemed to have a deficiency-preventative effect.  
 
V. Moize et al. (2012) The aim of this study was to compare the dietary intake 
(energy, macro- and micronutrients) and the micronutrient abnormalities for LSG 
and RYGB patients. The dietary intake was assessed on the basis of food records and 
diet journals, and a registered dietician guided the patients and evaluated their 
results. All surgeries were performed at a Spanish University hospital, and a total of 
355 patients entered the study. The choice of surgical procedure was not done at 
random, but patients with a BMI > 55, increased operative risk or an enlarged liver 
underwent the LSG procedure. All patients were prescribed a uniform daily 
supplement, in addition to a monthly vitamin B12 injection. Patients were assessed at 
baseline, 6, 12, 24, 48 and 60 months post-surgery, and the micronutrient 
parameters measured were hemoglobin, ferritin, calcium, vitamin B12, 25-OH-D and 
PTH. 
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Of the 355 patients enrolled in the study, only 61 patients underwent LSG, 
while 294 had the RYGB procedure. Due to inclusion criteria for the LSG procedure, 
there was a significant difference in the baseline demographics between the two 
groups. Patients in the LSG had significantly higher absolute weight, BMI and excess 
body weight. There were also significantly more micronutrient abnormalities among 
the LSG patients than the RYGB patients, which the authors contributed to the 
difference in baseline weight parameters.  
The rates of micronutrient abnormalities were very similar between the two 
groups, with 25-OH-D deficiency and elevated PTH being the most common 
abnormalities. In this study, the values of 25-OH-D were divided into three 
categories; > 30ng/mL was sufficient, > 10 to < 30 ng/mL was insufficient and < 10 
ng/mL was defined as being deficient. At baseline, 93 % of LSG patients and 91 % of 
RYGB patients had levels < 30 mg/mL. Despite the use of supplementation, the 
majority of study participants had insufficient or deficient 25-OH-D levels 
throughout the study. Similar to other studies, the values of the specific 
micronutrients tended to fluctuate throughout the follow-up period, thus making it 
difficult to assess whether patients actually improved or worsened. The drop-out 
rates were 16 %, 41 % and 66 % for the LSG patients at 2, 3 and 5 years, respectively 
making the long-term results less reliable.  
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J. Ruiz-Tovar et al. (2012) The aim of this prospective study was to evaluate 
the calcium metabolism parameter pre- and post-LSG. This Spanish study consisted 
of 30 female patients who meet with a dietician on a regular basis to ensure each 
patient was on a calorie-reduced and protein rich diet. In addition, a uniform 
vitamin and mineral supplementation was prescribed to all patients. Patients were 
assessed at 3 and 6 months post-surgery, and the micronutrient parameters 
measured were ferritin, calcium, vitamin D, PTH and vitamin B12. Prior to 
undergoing surgery, 96.7 % of the patients had vitamin D deficiency and 20 % had 
elevated PTH. The proportion of abnormalities kept decreasing post-surgery. By 3 
months, only 13.2 % had vitamin D deficiencies and 6.6 % had elevated PTH. 
However, 3.3 % (one patient) presented with newly developed ferritin deficiency. By 
six months, only one patient had vitamin D deficiency. The only significant changes 
following LSG was for vitamin D and PTH. A correlation analysis was done on weight 
loss and vitamin D following LSG. There was a significant (p < 0.05) inverse 
correlation after 3 months; as the weight decreased, the blood values of vitamin D 
increased. The study’s authors also suggested that the vitamin and mineral 
supplements provided where capable of treating or avoiding most of the 




Saif et al., (2012) The aim of this study was to evaluate certain micronutrient 
parameters following LSG. Eligible patients were divided into three groups, 
determined by their follow-up times; 1 year, 3 years and 5 years post-LSG. However, 
some patients were assessed on their micronutrient status more than once, and thus 
are entered in more than one follow-up group. No uniform supplementation was 
prescribed, but patients were advised to start a multivitamin regimen immediately 
after surgery. Adherence to this regimen was documented at each follow-up; 28.9 %, 
42.9 % and 63.3 % at 1, 3 and 5 years, respectively. The micronutrient parameters 
measured were hemoglobin, ferritin, PTH, calcium, vitamin B12 and vitamin D.   
A total of 82 patients entered the study, with the majority of patients being 
female (55 vs. 27). There was a significant drop-out rate at each of the three follow-
up points, and only 35, 27 and 30 patients were available for assessment at 1, 3 and 
5 years respectively. The most common abnormality at baseline was vitamin D 
deficiencies (75 %) and elevated PTH (51.5 %). There were no measurements for 
vitamin B12 at baseline, making it difficult to assess the follow-up data properly. 
Despite a change after the first and third year post-LSG for hemoglobin and PTH, the 
overall number of abnormalities at the 5-year follow-up was similar or higher than 
the baseline proportion. Overall, hemoglobin and calcium concentrations remained 
stable throughout the study. Ferritin (F) and vitamin D values increased, while 
ferritin (M) and PTH tended to decrease. There was no correlation between 
supplement use and blood levels of the vitamin D (p = 0.37) or PTH (p = 0.74).  
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P. W. J. van Rutte et al. (2014) The aim of this study was to determine the 
proportion of patients with micronutrient-related deficiency prior to LSG, and assess 
the evolution within the first 12 months following LSG. A total of 407 patients 
underwent the procedure at the same hospital in The Netherlands, but only 200 
patients returned for a follow-up visit within he first 12 months post-operatively. 
Patients who did not return for a follow-up visit, and patients with a RYGB revision, 
were excluded from the study. Patients were restricted to a liquid diet in the first 3 
post-operative weeks and instructed to initiate a supplement regimen consisting of 
multivitamins and minerals. Any micronutrient-related deficiency was defined as a 
blood value below the normal reference value, and the variables measured were 
hemoglobin, MCV, ferritin, calcium, vitamin B12, vitamin D and PTH.   
At baseline, the most common deficiency was vitamin D, with 81 % of 
patients presenting with blood values below 50 nmol/L. Of these patients, 55 % 
were severely deficient, meaning a vitamin D value below 30 nmol/L. Elevated PTH 
levels were found in 28.5 % of patients, the majority of whom also had deficient 
levels of vitamin D. Other deficiencies observed were vitamin B12, ferritin (all 
female), MCV and hemoglobin with 11.5 %, 7 %, 5.5 % and 5 % of patients, 
respectively. 
Within the first 12 months of surgery, significant improvements were 
observed only for vitamin D and PTH, 81 % vs. 36 % and 28.4 % vs. 17.9 %, 
respectively. The distribution of deficiencies 12 months post-LSG were: vitamin B12 
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(11.5 %), ferritin (8 %, all female), hemoglobin (6.5 %), MCV (2 %) and calcium (2 
%). The proportion of patients with other deficiencies did not change significantly 
post-LSG, although a significant number of patients (7 %) developed a vitamin B12 
deficiency in this period. Overall, almost 20 % of patients developed a deficiency in 
the follow-up period, despite being supplemented. The most common newly 
developed deficiencies were vitamin D (15 %), vitamin B12 (7 %) along with excess 
PTH (6.5 %). Overall, patients presented with micronutrient-related deficiencies 
prior to LSG. These deficiencies were continuingly present within the first 12 
months following LSG, along with a significant number of newly developed 
deficiencies.  
The main limitation according to the authors, is the inability to determine of 
the improvements observed were due to weight loss or the use of supplementation. 
The dosages and brand of supplementation was not determined nor was the dietary 
intake history. However, the significant number of newly developed deficiencies 
post-LSG suggests that the supplementation used was not sufficient in treating 







Table 2. 4  
Summary of changes in the biochemical parameters post-LSG from the 11 identified studies. 
 25-OH-D/ 
Vitamin D 
PTH Calcium Ferritin Hemoglobin MCV Vitamin  B12 
Aarts et al. ? ? ? N/A   ? 
Damms-Machado 
et al. 
 N/A Normal N/A N/A N/A  
Gehrer et al.   Normal N/A N/A N/A  
Capoccia et al. /- N/A /- N/A /- 
 
N/A  








- N/A ? 
Kehagias et al.  N/A     N/A - 
Ruiz-Tovar     N/A N/A  











PTH Calcium Ferritin Hemoglobin MCV Vitamin  B12 
Moize et al.      N/A  
Leivonen et al. ? N/A ? N/A ? ? ? 
van Rutte et al.       - 
















Note: N/A = Parameter not measured in given study. ? = No baseline measurements presented.  = Decreasing proportion 
of patients with abnormal blood levels.  = Increasing proportion of patients with abnormal blood levels.  = Increasing 
blood levels.  = Decreasing blood levels.  = Fluctuating results. - = Stable/No changes. Some studies report both 
changes in blood levels and change in status, thus results for both are presented in table.
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There are some inconsistencies regarding the possible changes in 
micronutrients-related parameters following LSG (Table 2.4). This is mainly due to 
the variations of the study protocol, variables measured and the follow-up period. 
Not all studies measure the biochemical parameters prior to surgery, thus only 
presenting the data for the follow-up visits, while others report both baseline and 
post-LSG results. The duration of the studies varies, although the majority of the 11 
studies report up to the 12-month follow-up. In addition, some of the studies report 
the number of deficiencies at each follow-up, while other report the laboratory 
changes in blood concentrations of the chosen parameters. This makes it difficult to 
compare results, as the number of abnormalities may not reflect the overall change 
of blood concentrations. 
Overall, the studies reported increasing values of 25-OH-D/vitamin D and 
calcium following LSG, which corresponded to a decrease in the proportion of 
patients with abnormally low 25-OH-D/vitamin D values, but an increasing 
prevalence of abnormal calcium levels. Three out of four studies reported that the 
proportion of patients with elevated PTH levels decreased following LSG, due to 
decreasing blood levels. Although three studies reported an increasing prevalence of 
vitamin B12 abnormalities post-LSG, there were fluctuating results regarding the 
changes in mean levels. In addition, the majority of the studies also reported an 
increase in the proportion of patients with abnormal ferritin, hemoglobin and 
abnormal MCV. 
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2.6. Medical Conditions Induced by Micronutrient Abnormalities 
The classification of micronutrient abnormalities is presented in Table 2.5. 
 
Table 2. 5  
Classification of micronutrient abnormalities.   
Abnormality classification 
1. Cause Primary 
 Secondary 
2. Type Excess/Toxicity 
 Insufficient/Deficient 
3. Nutrition Vitamin 
 Trace element 
 Mineral 
4. Degree Mild 
 Moderate 
 Severe 
5. Duration Acute 
 Sub-acute 
 Chronic 
6. Outcome Reversible 
 Irreversible 
Note: (McLaren, 1988) 
 
2.6.1 Metabolic Bone Disease 
Vitamin D deficiency can have a significant impact on bone health due to its 
role in calcium absorption. A decrease or deficiency of vitamin D leads to decreased 
calcium absorption. This initiates a chain-reaction leading to ostoemalacia 
(inadequate mineralization of the bone), hypocalcemia and eventually osteoporosis 
(Pressman & Adams, 1990; Salzman et al., 2013).  
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2.6.2. Anemia 
Iron deficiency anemia is one of the most common complications following 
bariatric surgery with many patients requiring supplementation to treat this 
condition. It can occur even if the patient has normal iron, hemoglobin, ferritin and 
vitamin B12 blood values (Lovette et al., 2012). There are many possible 
explanations for this, and it might be a combination of more than one. One 
explanation for anemia and iron deficiency following bariatric surgery, is the fact 
that most mal-absorptive surgeries remove the part of the small intestine where 
iron is mainly absorbed. This could be why iron deficiency is more common 
following gastric bypass than the gastric banding, where the intestine is not altered. 
Other possible explanations are reduced hydrochloric acid from the gastric pouch, 
inflammation of the intestines and a lack of sufficient dietary sources (Koch & Finelli, 
2010; Lovette et al., 2012; Salzman & Karl, 2013). 
Intrinsic factor is needed in order for vitamin B12 to be absorbed. This is 
produced by the gastric parietal cells in the stomach pouch, which is removed in 
bariatric surgeries such as RYGB and LSG. This can potentially lead to pernicious 
anemia, which can be caused by the vitamin B12 deficiency related to the loss of 




2.7. Micronutrient-related parameters 
Micronutrient-related parameters are often categorized as either direct or 
indirect nutrients. Direct nutrients are those that cannot be produced in sufficient 
quantities by the human body, thus they must be ingested through diet. Indirect 
nutrients can be produced in the human body, but may also be derived from diet 
(Biology Online, 2011). The indirect nutrients can reflect the micronutrient status in 
an individual, but could also reflect other aspects. For the parameters measured in 
this study, the direct parameters are calcium, vitamin B12 and ferritin, while the 
indirect parameters are vitamin D (25-OH-D), PTH, hemoglobin and MCV (Table 
2.6). However, for the purpose of the current study, these parameters will be 
categorized according to their interaction with each other. Thus, bone health 
parameters are grouped as follows: 25-OH-D, calcium and PTH, while hematological 
parameters include ferritin, hemoglobin, MCV and vitamin B12.  
Micronutrient-related deficiencies can lead to numerous conditions, such as 
anemia, neurological conditions and impaired bone health, ranging from mild to 
severe and chronic in nature. Due to this, supplementation of multivitamins and 
minerals is very common following most bariatric procedures. However, excessive 
supplementation can potentially cause hypervitaminosis and toxic concentrations of 
micronutrients, which can lead to several other medical conditions, such as ataxia, 
alopecia and hepatomegaly (Aarts et al., 2011; Koch & Finelli, 2010; Pressman & 
Adams, 1990). 
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Table 2. 6  
Summary of the select micronutrient and biochemical parameters measured in this study. 
 Involvement Low levels High levels 
Direct parameters 
Vitamin B12 Released in the gastric 
pouch.  
Absorption assisted by 
intrinsic factor 




High levels without 
supplementation are 
unusual, but can occur with 
some liver disorders, 
leukemia and diabetes. 
25-Hydroxyvitamin D 
(25-OH-D) 
The active form (calcitriol) is 
made by converting 25-OH-
D, which is determined by 
levels of calcium and PTH 
Can lead to hypocalcemia, 
ostoemalacia and 
osteoporosis. 
Abnormally high levels are 
unusual in non-
supplemented individuals. 
Calcium Bone health, coagulation 
mechanism and neurological 
system. Involved in most 
bodily processes.  
Negative feed-back 
mechanism with PTH. 
Can lead to hypocalcemia, 
ostoemalacia and 
osteoporosis. 
Calcium levels increase as a 
response to high PTH levels. 
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 Involvement Low levels High levels 
Indirect parameters 
Ferritin Indicator of iron storage. 
Acute phase reactor. 
Usually low when iron levels 
are low. 
Can be elevated even when 
iron levels are normal. Can 
be high with infections. 
Hemoglobin Transportation of oxygen from 
lungs to tissue 
Anemia Can occur with bone 
marrow malfunctions, heart 
failure, liver and kidney 
cancer etc.  
MCV Average volume of the red 
blood cells 
Can occur with iron 
deficiency 




Important factor in calcium 
absorption 
When calcium levels are too 
high, the amount of PTH 
secreted decreases. Low 
levels are seen with 
hypoparathyroidism and 
after thyroid surgeries. 
When calcium levels are too 
low, the amount of PTH 
secreted increases 
Note: [Christakos et al., 2013; Damms-Machado et al., 2012; Family Practice Notebook, 2013; Health Line, 2014; Health 
Link (a), 2013; Koch & Finelli, 2010; Lovette et al., 2012; Mayo Clinic (a), 2013; Mayo Clinic (b), 2014; McLaren, 1988; 
Medicine Net (a), 2013; Medicine Net (b), 2013; Pressman & Adams, 1990; Ruiz-Tovar et al., 2012; Saif et al., 2012; 
Salzman & Karl, 2013; Shankar et al., 2010; Shifflet & Wum, 2009; Swaminathan, 2011] 
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2.7.1. Bone health 
Vitamin D is present in the human body in two forms; vitamin D2 
(ergocalciferol) and vitamin D3 (cholecalciferol). The vitamin D derived from either 
ultra violet light or diet is converted in the liver to 25-OH-D (calcidiol). When 
determining vitamin D concentrations in the blood stream, it is most often the 
concentrations of 25-OH-D that is reported, as it have a longer half-life. Many obese 
individuals have insufficient levels of Vitamin D, due to either poor diet or 
insufficient sun exposure (Coupaye et al., 2013; Swaminathan, 2011). Another 
explanation may be that because vitamin D is fat-soluble, some of it is sequestered in 
the fat cells and only a small portion reaches the blood stream. Absorbed vitamin D 
reaches the fat cells first and the remnant goes to the liver; thus the more fat cells, 
the more Vitamin D is sequestered and it has been reported that 25-OH-D is reduced 
by up to 57 % in obese individuals (Ruxton, 2011; Vix et al., 2014). Some studies 
suggest that as an individual loses weight, the levels of vitamin D increases. 
However, it is unclear whether this is due to a release of stored amounts, or because 
declining fat stores means that less vitamin D from the sun or diet is trapped in the 
fat (Coupaye et al., 2013; Damms-Machado et al., 2012; Ruiz-Tovar et al., 2012; 




As vitamin D can be synthesized in the skin as a result of sun exposure, the 
blood levels can have seasonal variations. As people are more exposed to the 
sunlight during the summer months, the blood levels can be higher when measured 
in summer and fall as compared to winter and spring (Lefebvre et al., 2014). In 
addition, there might also be some geographic variation, as people living near the 
equator are more exposed to sunlight than those living in higher latitudes (Kimlin, 
2008; Newhook et al., 2009). Studies have shown that the seasonal variations are 
more pronounced at higher latitudes, as the UV exposure needed to provide 
sufficient levels of 25-OH-D are reduced during the winter months (Kimlin, 2008; 
Huotari & Herzig, 2008). In fact, it has been reported that the UV exposure from in 
countries below 35° North latitudes, is sufficient to maintain sufficient 25-OH-D year 
round. On the other hand, the UV exposure is reduced north of the 35° latitude mark, 
and at latitude of 41.9° North, sufficient 25-OH-D synthesis from UV exposure is not 
possible from November to February (Ross et al., 2011; Tsiaras & Weinstock, 2011). 
With Newfoundland & Labrador being located at latitude of 46° - 61° North, there is a 
possibility of insufficient synthesis of 25-OH-D beyond November through February.  
 
According to the 2009-2011 CHMS, Cycle 2, about one third of Canadians 
have blood levels of 25-OH-D below the normal reference value (< 50 nmol/L). This 
prevalence varied according to seasons, with 40 % classified as having insufficient 
levels (15 % of whom were deficient) from November to March, compared to 25 % 
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with insufficient levels (6 % of whom were deficient) from April to October [Jans & 
Pearson, 2013; Statistics Canada (b), 2013]. In addition, a study conducted in the 
Canadian province of Newfoundland & Labrador showed significant differences 
between the 25-OH-D levels in winter and summer months (Newhook et al., 2009). 
The production of active vitamin D (calcitriol) is dependent on the levels of 
calcium and PTH, among others. When calcium is low and PTH is high, the 
production of calcitriol increases (McLaren, 1988; Ruxton, 2011; Swaminathan et al., 
2011). About 30 % - 40 % of dietary calcium is absorbed in the intestinal tract, and 
25-OH-D assists in the synthesis of a specific protein involved in this absorption, 
while the rest is usually excreted through feces (McLaren, 1988; Swaminathan et al., 
2011). The amount of calcium stores in the body has an inverse relationship with 
parathyroid hormone (PTH). If calcium stores are too low, more PTH is secreted in 
order for the bones to release more calcium and vice versa [Health Link (a), 2013; 
Swaminathan, 2011]. This means, that if PTH is elevated, it is most likely due to 
insufficient intake or absorption of calcium or 25-OH-D, or both.  
 
2.7.2. Hematological parameters 
Ferritin is an indicator of iron storage and is often measured along with iron, 
total iron binding capacity and transferrin. Ferritin can be elevated even when iron 
concentrations are normal. Because it is an acute phase protein, the concentrations 
will usually increase when an infection or liver disease is present (Shifflet & Wum, 
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2009; Swaminathan, 2011; Web MD, 2013). In addition, ferritin can be elevated in 
certain chronic diseases, where inflammation prevents the irons stores in the bone 
marrow from being released.  
Hemoglobin is an iron-containing protein in the red blood cells responsible 
for the transportation of oxygen from lungs to tissue. When the spleen removes the 
red blood cells, the iron is transported back to the liver by transferrin, where it will 
be used in the production of new red blood cells [Mayo Clinic (a), 2013; Medicine 
Net (a), 2013]. As the MCV can decrease with iron deficiency and increase with 
vitamin B12 deficiency, the MCV can be normal if both these conditions are present. 
However, if this were the case, hemoglobin concentrations would be lower than 
normal.  
Vitamin B12 is also referred to as cobalamin and is the largest of the vitamins. 
It is bound to protein in the food we ingest and is released in the gastric pouch by 
the stomach acid. Intrinsic factor from the parietal gastric cells assists in the 
absorption that occurs in the small intestine (McLaren, 1988; Shankar, 2010). After 
the absorption, vitamin B12 reaches the liver where it is stored, until release is 
necessary due to an unexpected drop in circulating concentrations. Due to the 
relatively large storage capacity, vitamin B12 deficiency may not be detectable for 




2.8. Non-alcoholic fatty liver disease 
Many obese individuals also suffer from non-alcoholic fatty liver disease 
(NAFLD), which is an accumulation of fat in the liver cells not caused by alcohol 
consumption. Due to its increased prevalence, it is now the most common cause of 
liver disease in Western countries (Kopec & Burns, 2011). The risk factors 
associated with the development of NAFLD include age (the prevalence tends to 
increase with age), gender (men are at a higher risk than women), ethnicity 
(Hispanics have the highest prevalence, while African-Americas have the lowest) 
and the metabolic syndrome (Masuoka & Chalasani, 2012; Mishra & Younossi, 2012; 
Paschos & Paletas, 2009). In addition to this, NAFLD have been associated with an 
increased risk of not just all-cause mortality, but also specifically cardiovascular and 
hepatic related mortality (Calori et al., 2011; Koehler et al., 2013). 
NAFLD is thought to be the hepatic manifestation of metabolic syndrome, 
which is the presence of three or more of the following: hypertension, obesity, 
dyslipidemia, increased waist circumference, Type 2 diabetes and insulin resistance 
(Franzini et al., 2011; Masuoka & Chalasani, 2013, Razavizade et al., 2012; Shifflet & 
Wu, 2009). Due to the fact that patients suffering from metabolic syndrome are at 
higher risk of developing NAFLD, treatment options are often targeted towards the 
resolution of this condition (Hafeez & Ahmed, 2012; Masuoka & Chalasani, 2012). 
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NAFLD is a general term used for a number of liver conditions, stretching 
from mild steatosis (fatty liver) to more severe conditions. When left untreated, 
NAFLD may progress to the more aggressive form, known as non-alcoholic 
steatohepatitis (NASH), which is estimated to occur in 5 – 37 % of the cases 
(Masuoka & Chalasani, 2013; Shifflet & Wu, 2009). The progression to NASH is 
thought to be a 2-step process, the first being simple steatosis – NAFLD. The second 
step is oxidative stress of the hepatic cells, which ends with inflammation, fibrosis, 
cirrhosis and eventually liver failure (Paschos & Paletas, 2009; Shifflet & Wum, 
2009; Swaminathan, 2011). Due to the range in severity of the disease, NAFLD is 
often categorized as one of three states: simple steatosis (fatty liver), NASH with 
inflammation and ballooned hepatic cells without fibrosis or NASH with 
inflammation and ballooned hepatic cells with fibrosis (Chisholm et al., 2012; 
Mahaling et al., 2013). 
 
Because NAFLD is mostly asymptomatic, the majority of obese individuals 
will never be diagnosed unless they are tested specifically for this condition. The 
clinical signs that might arise are vague, and include fatigue and abdominal pain 
(Kopec & Burns, 2011; Mahaling et al., 2013; Paschos & Paletas, 2009). Studies have 
shown that 17 – 40 % of the general population suffer from NAFLD, while the 
prevalence among the obese population might be as high as 75 – 95 % (Chavez-
Tapia et al., 2010; Mishra & Younossi, 2012; Mummadi et al., 2008; Paschos & 
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Paletas, 2009; Schattenberg & Schuppan, 2011; Shifflet & Wu, 2009). The prevalence 
of NASH is more difficult to determine, as many studies combine NAFLD and NASH 
as simply “fatty liver disease’, but is estimated to between 10 and 37 % of the obese 
population (Chisholm et al., 2012; Masuoka & Chalasani, 2013; Mummadi et al., 
2008; Pillai & Rinella, 2009; Schattenberg & Schuppan, 2011). Among individuals 
with NASH as many as 15 – 50 % will progress to liver cirrhosis (Pillai & Rinella, 
2009; Shifflet & Wu, 2009; Swaminathan, 2011). The prevalence of these conditions 
is expected to increase parallel to the increase in risk factors (Kopec & Burns, 2011; 
Pillai & Rinella 2009; Shifflet & Wu, 2009). 
 
2.8.1. Diagnosis 
To diagnose NAFLD or NASH requires a combination of tests, and the choice 
of diagnostic tools varies among studies. The gold standard is a liver biopsy, where 
the severity of the conditions can be determined, and it is also the only way to 
accurately establish the diagnosis of NASH (Chalasani et al., 2012; Hafeez & Ahmed, 
2013; Kopec & Burns, 2011; Masuoka & Chalasani, 2013). Diagnostic imaging, such 
as ultrasound, CT or MRI scans are often used instead or in combination with biopsy, 
however, these can only determine if there is an accumulation of fat in the liver 
(Chalasani et al., 2012; Hafeez & Ahmed, 2013; Paschos & Paletes, 2009). 
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Certain biochemical parameters are also frequently used, including alanine 
transaminase (ALT), alkaline phosphatase (ALP), gamma glutamyl transpeptidase 
(GGT), bilirubin, low-density lipoprotein (LDL), triglycerides and high-density 
lipoprotein (HDL) (Kopec & Burns, 2011; Mahaling et al., 2013). Most often, a 
combination of two or more are used, in order to rule out any other suspicions. Most 
of these parameters are also found in other parts of the human body, and cannot 
alone indicate liver health (Paschos & Paletas, 2009; Swaminathan et al., 2011). In 
addition, it is important to note that some individuals with NAFLD or NASH might 
have normal levels of some of these parameters (Franzini et al., 2011; Masuoka & 
Chalasani, 2013; Paschos & Paletas, 2009).  
There is currently no perfect diagnostic tool or a general guideline, as the 
gold standard is invasive and expensive. Liver biopsies are often performed on the 
basis of abnormal biochemical liver parameters or diagnostic imaging indications 
(Chalasani et al., 2012; Mahaling et al., 2013; Masuoka & Chalasani, 2013; Shifflet & 







2.8.2. Treatment options 
Several treatment options for NAFLD and NASH have been studied, including 
lifestyle (e.g. diet, exercise), pharmacologic (e.g. Thiazolidinedione or Metformin) 
and surgical interventions (e.g. gastric bypass). They all aim for either a reduction in 
weight, waist circumference or improvement of Type 2 diabetes and metabolic 
syndrome (Kopec & Burns, 2011; Masuoka & Chalasani, 2013; Schattenberg & 
Schuppan, 2011). The most promising option is significant weight loss, which shows 
an improvement in the biochemical parameters, fibrosis and inflammation. In one 
study, a weight loss of 10.1 % after 6 months of dieting resulted in a significant 
decrease in liver enzymes and lipids (Ghaemi et al., 2013). However, significant 
weight loss can be difficult to obtain and maintain through lifestyle changes alone 
(Chalasani et al., 2012; Pillai & Rinella, 2009; Schattenberg & Schuppan, 2011).  
A significant and sustained weight loss can best be achieved by bariatric 
surgery, which also improves obesity related co-morbidities (Hafeez & Ahmed, 
2013; Kazaks & Stern, 2013; Pillai & Rinella, 2009; Snyder-Marlow, et al., 2010). 
Although not used as a treatment tool in clinical practice, the weight reduction 





2.8.3. Biochemical parameters 
As previously presented, there are several biochemical parameters used in 
the diagnosis of NAFLD and NASH. These included liver enzymes, lipids and other 
biochemical parameters. NAFLD is often associated with elevated levels of ALP, ALT, 
GGT and triglycerides, although none of these parameters are exclusive for this 
condition (Franzini et al., 2011; Hoofnagle et al., 2013; Kopec et al., 2011; Paschos et 
al., 2009; Razavizade et al., 2012). However, several studies have shown that these 
parameters tend to change following different types of bariatric surgical procedures. 
(Table 2.7) 
 
Table 2. 7  
Laboratory changes in select liver-related parameters following bariatric surgery. 
 RYBG GB LSG 
Bilirubin ? ? ? 
ALP ? ? ? 
ALT Decreasing/? Decreasing/? Decreasing/? 
GGT ? ? ? 
LDL Decreasing/? Decreasing/? Decreasing/? 
HDL Increasing/? Increasing/? Increasing/? 
Triglycerides Decreasing/? Decreasing/? Decreasing/? 
Note: ? = Conflicting or unknown results. (Chisholm et al., 2012; Hafeez & Ahmed, 




ALP is typically produced in the bone, liver, placenta and intestine, but is 
more commonly known as an indicator for liver health. Elevated levels can be 
caused by a number of conditions such as bone disease, vitamin D deficiency, 
obstruction of the bile tract, hepatitis and cirrhosis (Merriam-Webster – ALP, 2006; 
Razavizade et al., 2012; Swaminathan, 2011). ALT is an enzyme found in most tissue 
throughout the body, but it is used in the evaluation of hepatocellular injuries when 
there is a destruction of the hepatic cells (Merriam-Webster – ALT, 2006). Hepatitis, 
diabetes, alcohol abuse and steatosis are some of the conditions that can cause 
elevated ALT levels (Cayman Chemistry – ALT, 2013; Swaminathan, 2011). 
 
GGT is another enzyme used as a liver indicator. High concentrations can be 
found in the liver, kidneys and pancreas, but GGT is present throughout the body, 
except for the bones. The highest serum GGT concentrations are seen in patients 
with alcohol abuse, where as many as 70 % of alcoholics have elevated 
concentrations. Due to this, it is very important to determine the patient’s alcohol 
use before diagnosing NAFLD or NASH. Bile obstruction, the use of certain drugs, 
cirrhosis and most forms of liver disease also increase serum GGT levels (Medline 




Total Bilirubin is mainly produced during the destruction of erythrocytes 
(red blood cells), and is transported to the liver bound to albumin. Here it is 
conjugated to form bilirubin mono- and deglucuronides before it is excreted to the 
bile. If there is an obstruction of the bile duct (cholestasis), the bilirubin cannot be 
excreted and is transported back to the blood. This deposition can cause jaundice 
seen as a yellowing of the tissue. Although bilirubin is often measured as part of the 
liver functioning test, it might be within the normal range despite the presence of 
liver disease [Kopec & Burns, 2011; Mayo Clinic (c), 2013; Swaminathan, 2011]. 
 
Most of the liver parameters are measured as a unit, as they might not be 
very indicative of anything on their own. For instance, GGT and ALP are often 
measured together due to the fact that they are both present in the liver. However, 
because ALP is also present in bones, while GGT is not, it assists in determining if the 
increased ALP is due to liver or bone conditions. Despite the increase in the 
parameters during liver disease, the increase itself does not necessarily indicate the 
severity or improvement/worsening of that specific condition [Mayo Clinic (c), 
2013; Medline Plus, 2013; Paschos & Paletas, 2009; Swaminathan et al., 2011]. 
In addition to these conventional liver parameters, other biochemical 
parameters are measured as well in the assessment of NAFLD. Ferritin is an acute 
phase inflammation indicator, and elevated ferritin levels are common in patients 
with NAFLD, despite normal iron levels (Chalasani et al., 2012). One review suggests 
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that ferritin levels might be elevated in as many as 60 % of patients with NASH 
(Kopec & Burns, 2011). A lipids profile is also commonly used, as an improvement in 
LDL, HDL and triglycerides would be expected with a reduction of fatty liver due to 
the possible improvement/resolution of insulin resistance (Razavizade et al., 2012).  
 
The improvement of NAFLD and NASH is often associated with an expected 
decrease in the blood concentrations of ALP, ALT, bilirubin, GGT, LDL and 
triglycerides, along with an expected increase in HDL blood concentrations 
(Chisholm, et al., 2012; Ghaemi et al., 2013; Mahaling et al., 2013; Razavizade et al., 
2012). Two studies have compared liver parameters and lipids with three different 
grades of NAFLD, as diagnosed by ultrasound (Mahaling et al., 2013; Razavizade et 
al., 2012). Overall increases in ALP, ALT, LDL and triglycerides values, and 
significant decreases in HDL were observed in both studies, when the diagnosis 
went from grade 1 to 3 (p = 0.001). The increase in ALT concentrations was also 
significant in both studies (p < 0.004), while the ALP and LDL increases were non-
significant. The study by Razavizade et al. (2012) found a significant increase in 
triglycerides concentrations as well (p = 0.001), but this increase was not significant 
in the study by Mahaling et al. (2013). In addition, Mahaling et al. (2013) found that 
the proportion of patients with abnormal lipid values increased with the severity of 
the NAFLD grade, for HDL, LDL and triglycerides. 
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Two studies have proposed novel approaches to determine the presence or 
absence of NAFLD, without having to use expensive, invasive and time-consuming 
methods like biopsy and ultrasound. (Bedogni et al., 2006; Borman et al., 2013) 
These novel methods use a combination of anthropometric measurements along 
with specific biochemical parameters. The first method was the Fatty Liver Index 
(FLI), which was proposed by Bedogni et al. (2006). Based on an Italian patient 
population consisting of 216 patients with and 280 patients without fatty liver 
disease, they created and evaluated a simple algorithm based on variables 
associated with fatty liver disease, such as ALT, GGT, BMI, waist circumference (WC), 
glucose, insulin, triglycerides and ethanol intake. BMI (kg/m2) and WC (cm) were 
the strongest risk factors, and along with triglycerides (Trig, mg/dL) and GGT (U/L), 
these variables were included in the final model:  
 
𝐹𝐿𝐼 = (
𝑒0.953 𝑥 ln(𝑇𝑟𝑖𝑔)+0.139 𝑥 (𝐵𝑀𝐼)+0.718 𝑥 ln(𝐺𝐺𝑇)+0.053 𝑥 (𝑊𝐶)−15.745
1 +  𝑒0.953 𝑥 ln(𝑇𝑟𝑖𝑔)+0.139 𝑥 (𝐵𝑀𝐼)+0.718 𝑥 ln(𝐺𝐺𝑇)+0.053 𝑥 (𝑊𝐶)−15.745
) 𝑥100 
 
The authors stated that this algorithm is easy to employ clinically, where it 
could be used as a “selection tool for ultrasonography” but not as a final diagnostic 
tool. They based their cut-offs on the accuracy of the FLI, specifically on the 
sensitivity, specificity and positive and negative likelihood ratios. The FLI is easy to 
use, as a FLI > 60 can be used to rule in fatty liver disease, while a FLI < 30 can be 
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used to rule it out. The limitation however, is the fact that it does not distinguish 
between fatty liver disease in general (hepatic steatosis), although ethanol intake 
was not found to be a significant factor in this patient population, and non-alcoholic 
fatty liver disease. 
 
While the FLI has an excellent accuracy for hepatic steatosis detection based 
on ultrasound diagnosis, Borman et al. (2013) set out to externally validate the FLI, 
by comparing the FLI in their Canadian patient population with the results from 
liver biopsies. They determined that the FLI was only weakly correlated with the 
histological findings in regards to the percentage of lipid droplets in the liver cells (r 
= 0.25, p < 0.001), NAFLD Activity Score steatosis grade (r = 0.28, p < 0.001) and the 
fibrosis stage (r = 0.18, p = 0.005). In addition to this, the FLI had a poor ability to 
discriminate between steatosis grades. The authors proposed a new cut-off of 79, 
which would increase the sensitivity to 81 % compared to 61 % when using the cut-
off of 60 as suggested by Bedogni et al. (2006). However, as this would decrease the 
specificity from 86 % to 49 %, they set out to establish a novel algorithm for the 
prediction of hepatic steatosis. Several variables were considered for this Steatosis 
Index (SI), including age, gender, BMI, ALT, GGT, ALP, triglycerides, cholesterol, 
glucose and the presence or absence of diabetes, but the final model included BMI 




𝑒1.698 𝑥 𝑙𝑛(𝑇𝑟𝑖𝑔)+1.714 𝑥 𝑙𝑛(𝐺𝑙𝑢𝑐𝑜𝑠𝑒)−1.044 𝑥 𝑙𝑛(𝐴𝐿𝑃)+3.879 𝑥 𝑙𝑛(𝐵𝑀𝐼)−10.940
1 +  𝑒𝑒




When comparing the SI to the histological findings, there was a moderate 
correlation with the percentage of lipid droplets in the liver cells (r = 0.45, p < 0.001) 
and the grade of steatosis (r = 0.46, p < 0.001), and the SI outperformed the FLI 
when detecting significant steatosis. This patient population consisted of patients 
with confirmed hepatic disorders, whereas the patients in the study by Bedogni et al. 
(2006) consisted of patients with and without liver diseases.  
Although the authors determined that the SI is superior to the FLI, they did 
not provide any cut-off for the SI scores. As the paper was published in 2013, it has 
not yet been externally validated. More studies utilizing both indices are needed, in 
order for them to be validated and for appropriate cut-off values to be determined 
and therefore clinically useful.  
 
A third study by Koehler et al. (2013) set out to validate the FLI as a tool for 
identifying NAFLD. In this study 34.9 % of the study sample were diagnosed with 
NAFLD based on ultrasound. Based on the cut-off for of FLI > 60 the presence of 
NALFD  as suggested by Bedogni et al. (2006), 32.6 % of the patients had NAFLD. In 
addition to this strong associated between FLI and the presence of NAFLD, the 
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sensitivity and specificity of a FLI > 60 predicting the presence of NAFLD in this 
study were 60.4 % and 82.3 %, respectively, which is similar to the 61 % and 86 % 
reported by Bedogni et al. (2006). As a secondary outcome in the study by Koehler et 
al. (2013), the authors also found a strong association between the FLI and the 
severity of NAFLD, which had not been reported previously.  
 
2.8.4. Current literature on NAFLD and bariatric surgery 
Studies looking at improvement in NAFLD and NASH following bariatric 
surgery have shown promising results, with an overall improvement in steatosis and 
fibrosis (Chavez-Tapia et al., 2010; Masuoka & Chalasani, 2013; Mishra & Younossi, 
2012; Mummadi et al., 2008; Pillai & Rinella, 2009). The prevalence of NAFLD in 
patients seeking bariatric surgery has been estimated to be as high as 90 %, with 5 
% of these patients presenting with cirrhosis (Chalasani et al., 2012). The impact of 
bariatric surgery on NAFLD and NASH is based on retrospective studies and case 
reports; however the surgical intervention, diagnostic tools, length of follow-up, 
outcome parameters and sample size varies greatly among the studies reviewed 
(Chavez-Tapia et al., 2010; Kopec & Burns, 2011; Mummadi et al., 2008; Pillai & 
Rinella, 2009). Most of the studies based their findings on histological results from 
liver biopsies, as this is the current gold standard. The outcomes most commonly 
reported in the studies were improvement of steatosis, fibrosis, inflammation, 
ballooning and NASH resolution/grade (Schattenberg & Schuppan, 2011; Pillai & 
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Rinella, 2013), while a few report worsening or progression of the same markers 
(Hafeez & Ahmed, 2012).  
Two meta-analysis assessing the overall effect of weight loss post bariatric 
surgery on NAFLD have been published, that include retrospective and prospective 
cohort studies, as no randomized clinical trials have been conducted to date 
(Chavez-Tapia et al., 2010; Mummadi et al., 2008). Both studies highlight the limited 
amount of evidence on this topic in the literature. As with most of the literature on 
bariatric surgery, the majority of studies included in these meta-analyses are based 
on the RYGB procedure, and only one of the studies included the sleeve gastrectomy 
(Mattar et al., 2005). 
 
The first published meta-analysis was conducted by Mummadi et al. (2008) 
and it included 15 studies. The main outcome was improvements and/or resolution 
in NAFLD, defined as steatosis, steatohepatitis and fibrosis. The authors pooled the 
data from the identified studies, to determine the overall effect of weight loss 
following bariatric surgery on NAFLD. Based on their findings, improvements were 
observed for steatosis (91.6 %), steatohepatitis (81.3 %), fibrosis (65.5 %), NASH 
(69.5 %) and resolution of steatohepatitis was observed in 69.5 % of patients, along 
with an overall BMI reduction of 19.11 – 41.76 %. However, due to varying biopsy 
protocols among the studies, there was no pooled analysis performed for fibrosis, 
and the 65.5 % improvement was based on only five studies that used needle biopsy.  
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Although 75 % of patients experienced an improvement of the histological 
features associated with NAFLD post bariatric surgery, the results may have been 
biased by several limitations identified by the authors. These include significant 
heterogeneity among the studies identified, significant publication bias, varying 
histological grading systems and different reasons for biopsies in the follow-up 
periods. In addition, because patients with diagnosed cirrhosis were excluded from 
the study, the effect of weight loss achieved by bariatric surgery is based on a patient 
population that was at a less advanced fibrosis stage. 
 
The second meta-analysis by Chavez-Tapia et al. (2010) was based on 21 
studies, 15 of which were also included in the meta-analysis by Mummadi et al. 
(2008), and focused on overweight and obese patients (BMI > 25 kg/m2) with NASH. 
The follow-up period ranged from 1 – 5 years, and only two studies performed more 
than one liver biopsy during this time period. Of these included studies, 
improvements in the liver function tests (ALP, ALT, GGT and Bilirubin) was 
observed in 11 studies while seven studies reported improvements in one or more 
components of the metabolic syndrome. 18 of the 21 studies reported significant 
improvements of the histological parameters, including steatosis (18 studies), 
histological markers of inflammation (11 studies) and fibrosis (six studies). In 
addition to this, 14 studies did not report any adverse events in the follow-up 
period.  However, four studies did report on a deterioration of the fibrosis stage, and 
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3 other studies observed a small proportion of patients with deterioration of 
histological and NASH global scores.  
Although both meta-analyses reported that the majority of patients 
experience improvements and/or resolutions of their pre-existing NAFLD or NASH, 
neither study provides a definitive conclusion about the beneficial or adverse effects 
that weight loss following bariatric surgery might have on NAFLD or NASH. This is 
due to the lack of scientifically strong evidence that could be provided by 
randomized clinical trials. 
 
Assessing the impact of other types of bariatric surgery on NAFLD is 
important. As the prevalence of LSG procedures increases, it is important to conduct 
studies examining the impact of LSG on NAFLD. Thus far, only two studies identified 
have included the LSG procedure. (Karcs et al., 2010; Mattar et al., 2005) Mattar et 
al. (2005) conducted a study to evaluate changes in liver disease following three 
bariatric surgery procedures; RYGB, LSG and LAGB (LapBand). Liver biopsies were 
performed during and post-surgery, with a mean follow-up of 15 ± 9 months. A total 
of 70 patients were included and had both the initial and second biopsy. Of the 70 
patients, 23 underwent LSG, 41 LRYGB and six LAGB. In addition to the liver biopsies 
and clinical assessments, blood samples were also analyzed for ALT, triglycerides, 
LDL and HDL. 
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48 patients (68.6 %) were diagnosed with metabolic syndrome at baseline, 
which improved significantly, with only 10 patients (14.3 %) diagnosed post-
operatively. A significant improvement of the histological findings was reported, as 
the severity of fibrosis and steatosis was reduced. 37 % of patients experienced a 
resolution of their previous steatosis and inflammation, while 20 % had a resolution 
of the pre-existing fibrosis. An important finding was that no patients experienced a 
progression or worsening of any pre-existing liver condition, which has been 
reported in other studies (Hafeez et al., 2012; Schattenberg & Schuppan, 2011).  
Most of the biochemical measurements were within the normal range at 
baseline, and these improved significantly post-surgery in all except ALT. Because 
mal-absorptive procedures usually lead to more significant weight loss, patients in 
the study who underwent LRYGB had greater overall improvement in outcomes 
than patients in the LSG and LAGB groups. 
 
 Karcs et al. (2010) conducted a study consisting of 236 patients undergoing 
LSG, 223 of whom with liver biopsies performed. Among these 223 patients, 35 
presented with normal liver histology, 77 with simple steatosis and 87 patients with 
NASH.  There was a significant correlation between NASH and elevated ALT and low 
HDL levels (p < 0.001 and p < 0.01, respectively). There was a significant decrease in 
BMI, and the levels of ALT and triglycerides, along with a significant increase in HDL 
levels within the first year (p < 0.001) The study is limited by the fact, that no follow-
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up liver biopsies were performed, thus making it impossible to draw any 
associations between the improvement in the biochemical parameters and 
NAFLD/NASH.  
In summary, weight loss is currently the best method for improvements in 
NAFLD status, and the most efficient method for a significant and sustainable weight 
loss is bariatric surgery. The assessment of blood values for specific biochemical 
parameters would be a less invasive and less expensive method for diagnosis and 
management of NAFLD. However, with only two identified studies assessing the 
biochemical parameters associated with NAFLD following LSG, there is a great need 




2.9. Research Questions 
A. Primary research question 
In patients ≥ 19 years of age with a BMI ≥ 40 kg/m2, or a BMI ≥ 35kg/m2 plus 
risk factors, who have undergone laparoscopic sleeve gastrectomy, is there a change 
in  select micronutrients (vitamins and mineral) and related biochemical parameters 
pre- and post-surgery? 
 
Specific primary research questions 
From baseline to 3 and 6 months post-LSG, is there an improvement in the 
blood values of the biochemical parameters associated with bone health; 25-
hydroxyvitamin D (25-OH-D), calcium and parathyroid hormone (PTH)? 
 
From baseline to 3 and 6 months post-LSG, is there a decrease in the 
proportion of patients with abnormal values of the parameters associated with bone 
health; 25-hydroxyvitamin D (25-OH-D), calcium and parathyroid hormone (PTH)? 
 
Is the change in 25-OH-D significantly associated with the seasonal variations 
in sunlight exposure or the use of vitamin-containing supplements?  
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Is there a correlation between weight lost and the change in 25-OH-D levels 
following surgery? 
 
From baseline to 3 and 6 months post-LSG, is there a deterioration of the 
blood values of the hematological parameters; ferritin, hemoglobin, mean cell 
volume (MCV) and vitamin B12 or do they remain stable? 
 
From baseline to 3 and 6 months post-LSG, is there an increase in the 
proportion of patients with abnormal values of the hematological parameters; 
ferritin, hemoglobin, mean cell volume (MCV) and vitamin B12? 
 
B. Secondary research questions 
Do patients, who have undergone laparoscopic sleeve gastrectomy, 
experience an improvement in the biochemical liver parameters associated with 





Specific secondary research questions 
From baseline to 3 and 6 months post-LSG, is there an improvement in the 
blood values of the biochemical parameters associated with non-alcoholic fatty liver 
disease; alanine phosphatase (ALP), alanine transaminase (ALT), gamma glutamyl 
transpeptidase (GGT), total bilirubin, high density lipoprotein (HDL), low density 
lipoprotein, (LDL) and triglycerides? 
 
From baseline to 3 and 6 months post-LSG, is there a decrease in the 
proportion of patients with abnormal values of the parameters associated with non-
alcoholic fatty liver disease; alanine transaminase (ALT), alanine phosphatase (ALP), 
gamma glutamyl transpeptidase (GGT), total bilirubin, high density lipoprotein 
(HDL), low density lipoprotein, (LDL) and triglycerides? 
 
Is there a correlation between weight lost and the change in the biochemical 





It is hypothesized that the biochemical values of 25-OH-D, PTH and calcium 
will improve post-LSG, the values of hemoglobin and MCV will decrease or remain 
stable and while the values of ferritin and vitamin B12 will fluctuate following LSG.  
It is also hypothesized that the proportion of patients with abnormal values 
of 25-OH-D and PTH will improve post-LSG, while the proportion of patients with 
abnormalities for calcium, vitamin B12, ferritin, hemoglobin and MCV will increase 
following LSG.  
 
It is hypothesized that the biochemical values of the biochemical parameters 
associated with non-alcoholic fatty liver disease following LSG, mainly decreases in 
ALT, GGT, LDL and triglycerides along with increases in HDL. 
It is also hypothesized that the proportion of patients with abnormal values 
of the biochemical parameters associated with non-alcoholic fatty liver disease, 





This chapter outlines the research design, the study population, the 
recruitment of the sample, study procedure and the surgical procedure. A 
standardized data abstraction form was used for data collection to gather the 
following information: patient demographics such as age, gender, employment 
status, level of education, history of co-morbid conditions; weight, height, waist 
circumference; fasting lipid levels, hemoglobin, MCV, ferritin; liver biomarkers 
including ALP, ALT, GGT, total bilirubin; other biochemical parameters such as 
calcium, PTH, vitamin B12, 25-OH-D; and supplement use. The nutritional guidance 
patients received before and after surgery will be described along with the data 
analysis plan and ethical considerations.  
 
3.1. Research Design 
The Newfoundland and Labrador Bariatric Surgery Cohort Study (NL BaSCo) 
is a population-based prospective quasi-experimental study using a pretest-posttest 
design without a control group. It began in May 2011 when the first LSG surgery was 
performed in the province. All surgeries take place at the Health Sciences Centre in 
St. John’s, Newfoundland. All analysis and results presented is from a sub-analysis 
conducted on data collected by others from the parent study.   
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3.2. Population and sample 
General Practice physicians (GP), or specialists, referred all patients 
potentially eligible for LSG to the Eastern Health multi-disciplinary bariatric care 
clinic. The bariatric nurse practitioner at this clinic performed a preliminary 
eligibility screening of all patients, using a set of preliminary inclusion and exclusion 
criteria: patients must be between 19 and 70 years of age, they must have a BMI 
between 40 – 60 kg/m2 (or BMI ≥ 35 kg/m2 plus comorbidities) and they must have 
attempted a previous, non-surgical, weight loss.  
Eligible patients were invited to attend a pre-surgical education orientation, 
where they were informed of the surgical procedure and its lifelong consequences. 
Participants, who were interested in proceeding towards bariatric surgery, were 
instructed to start keeping food records and start a food journal, which they were 
instructed to bring with them, along with a list of their medications, during their 
initial clinic visit. Each patient met with the nurse practitioner for further 
assessment, including blood work and a sleep study to identify and treat any sleep 
apnea disordered breathing if necessary. If any other medical concerns were 
identified, patients were consulted by the appropriate specialist (e.g. cardiologist, 





Patients then met with a bariatric surgeon, and if deemed to be a surgical 
candidate, they signed a consent form to undergo bariatric surgery, specifically LSG. 
Patients had to meet a second set of inclusion and exclusion criteria before they 
could be considered a surgical candidate. They must be medically, psychologically 
and emotionally prepared, they must be committed and motivated for the follow-up 
requirements, they must be able to understand what the surgery is about and what 
it requires pre- and post-operatively, and female patients cannot be pregnant or 
plan on becoming pregnant within the first 24 months post-surgery (NL Bariatric 
Surgery Program, 2013). 
 
3.3. Recruitment for the research study 
Once the patients had been deemed eligible for surgery, a member of the 
clinical team approached eligible patients and informed them of the research study. 
Interested patients gave permission for the research nurse to approach them with 
additional information, such as a detailed explanation of the research study, an 
introductory letter from the researcher and a consent form, which contained more 
information. If permission was granted, patients met with the research nurse at 
their surgical appointment, where they would have had 24-48 hours to read through 
the material provided to them. Once the surgeon had given final approval for LSG 
and obtained written surgical consent, the research nurse met with the potential 
participant to answer any questions and obtain informed consent to participate in 
the cohort study. Baseline data was collected after informed consent was given.  
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3.3. Data Collection 
Before undergoing the surgery, a standard of care routine blood work was 
completed for all patients for a large number of biochemical parameters. For the 
purpose of the current thesis, the focus will be on blood work completed in order to 
assess select biochemical parameters associated with micronutrient status and 
NAFLD (Table 3.1).  
 
Table 3. 1  
Select biochemical parameters measured in the NL BaSCo study and their normal 
reference values. 
Parameter Unit Female Reference Male Reference 
ALP U/L < 150 < 150 
ALT U/L < 55 < 55 
Calcium* mmol/L 2.12 – 2.62 2.12 – 2.62 
Ferritin μg/L 11 – 307 24 – 336 
GGT U/L < 32 < 32 
Hemoglobin g/L 120 – 160 140 – 180 
MCV fL 81 – 99 80 – 97 
PTH ng/L < 72 < 72 
Total Bilirubin μmol/L < 20 < 20 
Vitamin B12 pmol/L > 107 > 107 
Vitamin D (25-
OH-D) 
nmol/L > 50 > 50 
Triglycerides mmol/L < 1.90 < 1.90 
LDL mmol/L < 3.4 < 3.4 
HDL mmol/L > 0.9  > 0.9  
Note: *As albumin blood concentrations can influence calcium, the calcium blood 
values measured were later corrected for albumin. 
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The role of the candidate was to access data from the main database, in order 
to conduct the statistical analyses needed to answer the research questions. All 
statistical analyses were done with direct consultation with a biostatistician, but 
were carried out by the candidate. The candidate was not directly involved in the 
collection of any data used in the overall study, and did not directly interact with the 
patients.  All baseline data were collected at the Health Science Centre in St. John’s, 
Newfoundland by the research team. To accommodate patients from rural areas, 
follow-up assessments were also conducted via TeleHealth and blood work analysis 
ordered by GP’s were collected at local hospital blood collection clinics. Results from 
any laboratory analysis outside the Health Sciences Centre were sent to the bariatric 
surgery clinic nurse practitioner. 
  
3.4. Methods 
Patients were assessed prior to undergoing LSG, as well as at several follow-
ups post-LSG. Anthropometric assessments were performed at 1-month post-LSG, 
and were continued with biochemical assessments at 3, 6, 12, 18 and 24 months. 
However, for the purpose of this thesis, only the data from baseline, 3 and 6 months 
assessments were included due to small samples sizes at the remaining follow-ups.  
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3.4.1. Surgical Procedure 
All surgical procedures took place at the Health Sciences Centre in St. John’s, 
Newfoundland. On average, three surgeries were performed each week, with an 
estimated 100 surgeries conducted per year. A multi-disciplinary team consisting of 
three bariatric surgeons, a nurse practitioner, a dietician and other related health 
care professionals, provided care to patients pre- and post-surgery. The LSG 
procedure was performed under general anaesthesia. A total of six trocars were 
used, along with a 42 French bougie to determine the sleeve size. An endoscopic GIA 
stapler with tri-staple technology was utilized, and the product was produced and 
copyrighted by Covidien. The resection of the stomach pouch was initiated about 7 
cm proximal to the pylorus, and an endoscopic air leak test was performed to 
confirm that the staple line is intact. If no leakage was detected, the resected part of 
the stomach pouch would be extracted from the abdomen, and the port sites are 
closed. On the first post-operative day, a gastrointestinal test was performed before 






3.4.2. Micronutrient guidance 
Pre-surgery 
At the pre-surgical orientation, patients received information about the 
surgery procedure and information about the importance of nutrition and how to 
read labels on food products. At Eastern Health, patients were not provided a 
uniform multivitamin supplement, but they were strongly encouraged to keep food 
journals and initiate a multivitamin regime. They were provided with a list of 
suggestions for certain supplement brands such as Centrum or Swizz multivitamin, 
Ensure Nutritional Drinks, etc. Before the surgery, all patients accepted for surgery 
were required to adhere to a week-long full-fluid diet. The reason for this is three-
fold (NL Bariatric Surgery Program: Orientation, 2013; Rickers & McSherry, 2012): 
to ensure patients were capable of consuming a very small amount of food and 
adhering to a very strict diet, to have patients lose some weight even before that 
surgery thus improving the outcome post-surgery and to shrink the liver before 
surgery in order to minimize the risk of complications during surgery.  
 
Post-surgery 
The day after the surgery, the dietician advised the patients on the strict diet 
that follows immediately after surgery, starting with an all-fluid diet for the first 4 
weeks. The patients were instructed what foods they were allowed to eat in the 
advancement from full-fluid to solid-foods. Patients met with the dietician 4 weeks 
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after the surgery and with the surgeon at 6 – 8 weeks post-operative (NL Bariatric 
Surgery Program, 2013; NL Bariatric Surgery Program: Full Fluid Diet, 2013; NL 
Bariatric Surgery Program: Soft Diet, 2013).  
 
3.4.3. Biochemical assessments 
The majority of biochemical assessments were performed at the Health 
Sciences Centre in St. John’s, but laboratory assessments were completed 
throughout the province. Due to this, there was varying analysis protocols used to 
analyze the same parameters. The analysis for 25-OH-D used the gold standard 
method of liquid chromatography coupled with tandem mass spectrometry, 
developed in-house (Personal correspondence with Dr. Edward Randell). 
Hemoglobin and MCV were both analyzed on the Beckman Coulter®HMX 
Hematology Analyzer, while ferritin, vitamin B12 and intact PTH were all analyzed on 
the Architect i System by Abbots Diagnostics. Calcium and the biochemical 
parameters associated with NAFLD were all analyzed on the Architect c System by 
Abbots Diagnostics, using different assays according to the parameters analyzed. In 
addition, the values of LDL were calculated on the basis of values of total cholesterol, 
HDL and triglycerides.  
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3.5. Data Analysis 
All continuous data is presented as mean ± standard deviation, while 
descriptive and nominal data is presented as absolute numbers and percentages. 
The laboratory measurements are presented as mean ± standard deviation along 
with the minimum and maximum values. The proportions of patients with blood 
values higher or lower than the normal references will be listed, along with the 
number of patients with normal blood values. A repeated measures analysis of 
variance (ANOVA) was used to compare continuous data at baseline with the two 
follow-up times (i.e. 3 and 6 months). For non-normally distributed data, the non-
parametric equivalent test (i.e. Friedman) was performed. This was done in 
combination with the Wilcoxon signed-rank test with Bonferroni correction with a 
significance value at 0.017. The McNemar test was used to determine any significant 
differences in categorical data, i.e. the proportions of biochemical abnormalities at 
baseline and post-LSG. One-way ANOVA was used to determine seasonal variations 
in 25-OH-D blood levels. 
In order to analyse the changes in 25-OH-D over time, univariate and 
multivariate generalized estimating equation (GEE) regression models were 
performed. Levels of 25-OH-D can be affected by a number of variables, but the only 
variables available in the current study were seasonal variations and the use of 
vitamin D-containing supplements.  Univariate analyses were conducted, and only 
significant predictors were adjusted for in the multivariate model.   
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The GEE is an expansion on the generalized linear model. A strength of the 
GEE model is that it does not assume that there is complete information on all 
patients, thus it includes all available data points regardless of individual missing 
data points. This means that if a patient has a missing data point at 3 months, the 
data from baseline and 6 months will stay in the model, whereas all data points on 
this patient would have been excluded by the repeated measures ANOVA. The model 
for these analyses used a normal linear link function, with a normal probability 
outcome distribution. The correlation structure was auto-regressive which assumes 
the correlation as of the time lag, and 25-OH-D was the dependent variable while 
time, seasons and supplement use were predictors (factors). The significance levels 
were determined by the Wald Chi2 test which is carried out in the GEE analysis.  
Univariate correlation analysis was used to determine any association 
between weight and 25-hydroxyvitamin-D status or any of the biochemical 
parameters associated with NAFLD. A repeated measures ANOVA was used to 
determine differences in weight change parameters and a one-way ANOVA was used 
to determine significant differences between seasonal variations in 25-OH-D blood 
levels. All statistical analysis was performed using IBM SPSS Statistics, version 19.0 
(SPSS, Armonk, NY: IBM Corp). Apart from the Bonferroni correction, a p-value < 
0.05 was considered significant for all analysis.  
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3.6. Ethical Considerations 
The provincial Health Research Ethics Authority (HREA) approved the 
Newfoundland & Labrador Bariatric Surgery Cohort Study via the subcommittee The 
Health Research Ethics Board (Appendix 3. 1). Patients were assigned a unique ID 
prior to any data entry by the research nurse collecting the data, and electronic 
versions of the master list were stored on a password protected computer and 
external hard drive. All data was de-identified by the research nurse and the unique 
ID was to ensure anonymity of the participants to the research staff. Only the 
research nurse had access to the master list. 
Data collected by the bariatric nurse practitioner and the research nurse, 
were forwarded in a de-identified manner to another member of the research team 
for entry into the database. Once the data was received, coded and entered into 
another database, copies of the coded abstraction forms were stored in a locked 
cabinet at the Patient Research Centre located at the Health Sciences Centre. The 
computer containing the databases was password protected and all files were 
backed up to an external hard drive as they were updated. Access to the databases 
was limited to the primary investigators and research staff. De-identified data used 




The first section of this chapter will present the demographic and 
anthropometric characteristics of the study sample, such as weight, co-morbidities 
and socio-demographics. The second part will cover the changes in micronutrient-
related parameters following LSG, by comparing the baseline values of the specific 
parameters to the values at 3 and 6 months post-LSG. The last section will address 
the changes in the biochemical parameters associated with NAFLD and NASH. 
 
4.1. Characteristics of the Sample 
By the end of May 2014, a total of 189 patients had undergone LSG and were 
approached to participate in the study. All but one patient consented, providing a 
99.5 % participation rate. Of the total number of patients followed through the 
study, the number of patients who had completed the laboratory assessments were 
127 (67.6 %), 109 (58 %) and 63 (33.5 %) at 3, 6 and 12 months post-LSG, 
respectively, but these numbers are expected to increase as the study progresses. A 
subgroup consisting of 95 patients had completed their baseline, 3 and 6 months 




Table 4. 1 
Baseline demographics of the study sample 
 Subgroup (95 patients) 
 Mean ± SD ± SD 
Age, years 44.9 ± 9.6 22 - 66 
BMI, kg/m2 49.3  ± 6.8 37.7 – 67.2 
No. of comorbidities 5.8 ± 3.0 1 - 16 
 n % 
Sleep Apnea 55 63.9 
Dyslipidemia 54 58.7 




Diabetes 33 35.1 
Coronary Heart Disease 5 5.3 
Fatty Liver 2 2.1 
Female 78 82.1 
Marital Status   
Married/Common-Law 71 75.5 
Separated/Divorced 14 14.9 
Single/Never Married 7 7.4 
Widowed 2 2.1 
Education Level   










 Subgroup (95 patients) 
 n % 
Employment status   
Full-time 48 51.1 
Disability leave (Temp. 
sick, short/long term) 
13 13.8 
Retired 10 10.6 
Other (part-time, school, 
home-maker, other) 
23 24.5 
Income   
>/= 80,000 24 25.5 
50,000 – 79,999 23 24.5 
30,000 – 49,999 20 21.3 
15,000 – 29,999 11 11.7 
< 15,000 3 3.2 
Note: All data except BMI is self-reported. SD = Standard Deviation. N = Number of 
patients. % = Percent of the sample population. 
 
The baseline demographics of the study sample are shown in Table 4.1. The 
majority of study participants were female (82.1 %), with a mean age and BMI of 
44.9 ± 9.6 years and 49.3 ± 6.8 kg/m2, respectively. The mean number of 
comorbidities was 5.8, with the most common being sleep apnea (63.9 %), 
dyslipidemia (58.7 %), hypertension (51.1 %), impaired glucose tolerance (39.8 %) 
and diabetes (35.1 %).  
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Almost half of the patients had achieved a college diploma or higher (48.4 %), 
while 23.7 % had completed high school or less. There was some range in the 
current household income for the patients, with half of the study population (50 %) 
having an income of $ 50,000 or more. The majority were married or in a common-
law relationship (75.5 %) and working a full-time job (51.1 %). 
 
4.2. Weight changes 
At each follow-up the patients had their height and weight measured, which 
was then used to calculate their BMI. Absolute weight and reductions in BMI were 
calculated, along with the percentage weight loss (Table 4.2). 
 
Table 4. 2Change in body weight (kg), BMI (kg/m2) and waist circumference 
 Baseline 3 months 6 months 
Absolute weight (kg) 135.7 ± 25.3 114.6 ± 21.8* 105.1 ± 20.6*† 
Absolute weight loss 
(kg) 
- 20.9 ± 5.7* 30.4 ± 8.5*† 
% weight loss - 15.4 ± 3.0 22.4 ± 4.5† 
Absolute BMI 
(kg/m2) 
49.3 ± 6.9 41.7 ± 6.1* 38.2 ± 5.7*† 
Absolute BMI loss 
(kg/m2) 
- 7.6 ± 1.8* 11.1 ± 2.8*† 
Waist circumference 
(cm) 
141.2 ± 16.6 122.1 ± 15.3 * 114.6 ± 13.9* 
% waist 
circumference loss 
- 13.5 18.8 
Note: Repeated ANOVA analysis. * = p-value < 0.05 when comparing data to baseline. 
† = p-value < 0.05 when compared to 3 months. BMI = body mass index.  
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There was a significant decrease in absolute weight comparing baseline to 
both 3 and 6 months post-LSG (p < 0.001). The weight loss was significant, with 
patients losing an average of 20.9 kg and 30.4 kg of their initial weight after 3 and 6 
months, respectively. The decrease in absolute BMI from baseline to 3 and 6 months 
post-LSG was also significant (p < 0.001), with patients loosing an average of 7.6 
kg/m2 by 3 months and 11.1 kg/m2 by 6 months post surgery. In addition, a 
significant decrease in waist circumference was observed at both 3 and 6 months 
post-LSG, with patients having lost 18.8 % of their initial waist circumference 6 
months following LSG. 
 
4.3. Changes in micronutrient-related parameters 
Micronutrient-related parameters were measured prior to surgery and at 3 
and 6 months post-operative. The baseline values were collected after the bariatric 
orientation, initial full-fluid diet and nutritional guidance from the bariatric team at 
the Health Science Centre. Because not all biochemical parameters were part of 
standard blood work and needed to be ordered additionally, some patients did not 
have all biochemical parameters measured at baseline and at each follow-up. The 
proportion of missing data ranged from 2.1 % at baseline to 8.4 % at 3 months and 
11.6 % at 6 months post-LSG. However, due to variation in routine laboratory 
protocols, 25-OH-D and PTH were not measured in all patients, with a proportion of 
missing data ranging from 1.1 % at baseline to 16.8 % at 3 months and 27.4 % at 6 
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months post-LSG. In order to reduce the impact of of missing data points, the GEE 
analysis was used to analyse the changes in mean blood values for 25-OH-D and PTH 
following LSG.  
The mean values for the seven micronutrient-related parameters were all 
within the normal range at baseline. Despite a change in blood values post-LSG, the 
mean values remained normal at 3 and 6 months for all parameters, except for the 
mean value of PTH (Appendix 4. 1). Further examination determined that at 
baseline, 53 patients (55.8 %) presented with one or more abnormality, the most 
common being elevated PTH (26.9 %) and low 25-OH-D (21.3 %). Some patients 
experienced an improvement or resolution of any pre-existing biochemical 
abnormalities in the follow-up period, with the proportion of patients with one or 
more abnormality decreasing slightly to 50.5 % and 46.3 % at 3 and 6 months post-
LSG, respectively (p > 0.05). 
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4.3.1. Bone health parameters  
Table 4. 3  
Changes in the proportion of patients with abnormal values of the parameters associated with bone health 
 Normal Reference  Baseline  
n (%) 
3 months  
n (%) 
6 months  
n (%) 
25-OH-D > 50 mmol/L N 94 79 69 
  Normal 74 (78.7) 70 (88.6) 68 (98.6) 
  Low 20 (21.3) 9 (11.4) 1 (1.4)* 
PTH < 72 ng/L N 93 89 87 
  Normal 68 (73.1) 55 (61.8) 55 (63.2) 
  High 25 (26.9) 34 (38.2) 32 (36.8) 
Calcium 2.12 – 2.62 mmol/L N 93 93 88 
  Normal 89 (95.7) 92 (98.6) 84 (95.5) 
  High 4 (4.3) 1 (1.1) 4 (4.5) 
  Low 0 0 0 
Note: McNemar analysis. N = Number of patients. N = Total number of patients. High = Levels higher than upper reference 
value. Low = Levels lower than lower reference value. Normal = Levels within the normal reference values. * = p-value < 
0.05 when compared to baseline. 
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From baseline to 3 and 6 months post-LSG, is there an improvement in the blood 
values of the biochemical parameters associated with bone health; 25-OH-D, calcium 
and PTH? 
From baseline to 3 and 6 months post-LSG, is there a decrease in the proportion 
of patients with abnormal values of the biochemical parameters associated with bone 
health; 25-OH-D, calcium and PTH? 
 
There were fluctuations in the mean blood levels of the bone health 
parameters throughout the study duration, but the individual changes will not be 
discussed here. The proportion of patients with 25-OH-D abnormality decreased 
post-operatively (Table 4.3), while the proportion of patients with elevated PTH 
increased initially (p <0.001 and p > 0.05, respectively).  
The mean values for 25-OH-D increased significantly from 69.6 nmol/L at 
baseline, to 78.4 nmol/L at 3 months and 81.1 nmol/L at 6 months post-LSG (p < 
0.001).  Mean PTH value increased initially by the 3-month follow-up from 62.9 ng/L 
at baseline to 74.1 ng/L (p < 0.001), before a modest decrease to 70.9 ng/L was 
observed at the 6-month follow-up (p > 0.05). There was a non-significant decrease 
in calcium concentrations by 3 months following LSG, however, an increase to 2.47 
mmol/L was observed by the 6-month follow-up. This increase was significantly 
higher than both the baseline concentration of 2.44 mmol/L (p > 0.05) and the 3-
month concentration of 2.43 mmol/L (p = 0.007). Despite these significant changes, 
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the mean concentrations were all within the normal range throughout the study 
(Appendix 4.1). 
Prior to surgery, 20 patients (21.3 %) had a lower than normal 25-OH-D 
blood concentration (Table 4.3). By 3 months post-LSG, the proportion had 
decreased to 11.4 % (p > 0.05) and a further decrease to 1.4 % was observed at the 
6-month follow-up (p < 0.001). At baseline, 26.9 % of the study sample presented 
with elevated PTH, but there was an initial increase to 38.2 % at the 3-month follow-
up (p > 0.05) and small decrease to 36.8 % at the 6-month follow-up. (p > 0.05). Only 
4 patients (4.3 %) presented with a calcium abnormality at baseline and there was a 
slight decrease to 1.1 % at 3 months and an increase to 4.5 % at 6 months following 
surgery, both non-significant.  
 
4.3.1.1. 25-hydroxyvitamin D 
Is the change in 25-OH-D significantly associated with seasonal variations in 
sunlight exposure or the use of vitamin D-containing supplements? 
 
Due to the fact that vitamin D can be synthesized in the skin from sunlight 
exposure, and that there can be seasonal variations in 25-OH-D values, the blood 
levels were compared by season. The actual dates of laboratory measurements were 
divided into the four seasons according to the equinoxes and solstices: Winter 
(December 21st to March 19th) Spring (March 20th to June 20th) Summer (June 21st to 
September 21st) Fall (September 22nd to December 20th). The seasonal variations of 
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25-OH-D were not significant at the assessments at baseline (p = 0.241), 3 months (p 
= 0.202) or 6 months post-LSG (p = 0.820) 
 
The use of supplementation may have an effect on the blood values of 25-OH-
D, as many multivitamins and over-the-counter supplements contain vitamin D. As 
the research literature suggests, many overweight and obese individuals suffer from 
insufficient levels of certain micronutrients. As these can be treated with 
supplementation, it was important to identify the number of study participants who 
were taking one or more supplements.  
There was no uniform supplementation provided to the patients 
participating in this study, but they were strongly encouraged to start a supplement 
regimen before they underwent LSG. More than half of the patients (55.3 %) were 
supplemented prior to undergoing surgery, and there was an increase in the overall 
use of overall supplements post-LSG, with almost all patients reporting taking one or 
more supplements at the 3 and 6 months follow-ups. (Table 4.4) The most 
commonly consumed supplement throughout the study was multivitamins. Apart 
from the multivitamin use, 18 patients (27.7 %) took a vitamin D supplement prior 
to surgery. The proportion of patients taking a vitamin D supplement increased 
post-operatively, with 35.5 % and 45.9 % taking vitamin D supplements at 3 and 6 
months, respectively.  
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Only a small proportion of the study sample (7.4 %) was taking vitamin B12 
supplements prior to surgery. Similar to many of the other supplements, vitamin B12 
supplement use increased to 10.9 % at 3 months and 16.5 % at 6 months post-LSG. 
It is however important to note, that most multivitamins contain vitamin D, calcium 
and vitamin B12. Some patients also reported using over the counter (OTC) 
supplements or herbals and 13 patients (13.8 %) took some form of OTC 
supplement or herbal at baseline. At the 3-month follow-up, 19.6 % of patients were 
on an OTC supplement regimen and this increased to 29.8 % at 6 months post-LSG.  
 
Table 4. 4  
Reported supplement use in study participants, n = 95 
 Baseline 3 months 6 months 
 n (%) n (%) n (%) 
Calcium 5 (5.3) 4 (4.3) 7 (8.3) 
Vitamin D 26 (27.7) 33 (35.5) 39 (45.9) 
Vitamin B12 7 (7.4) 10 (10.9) 14 (16.5) 
Multivitamin 42 (44.7) 88 (94.6) 78 (91.8) 
OTC or herbals 13 (13.8) 18 (19.6) 25 (29.8) 
Overall 52 (55.3) 92 (98.9) * 84 (97.7) * 
Note: n = number of patients. % = proportion of patients. All data is self-reported. 
OTC = Over the counter. % = Percentage of the study sample asked. * = p-value < 
0.05 when compared to baseline. 
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The proportion of patients presenting with low 25-OH-D were assessed at 
each time-point, to determine the effect of supplement use. At baseline, the 
proportion of abnormalities was somewhat equally distributed among the 
supplemented and non-supplemented patients, with nine supplemented patients 
presenting with low levels compared to 11 patients with low levels who were not 
supplemented. However, the effect of supplement on the proportion of patients with 
low 25-OH-D was not able to be determined in the follow-up period, as all but one 
patient was taking a supplement that likely contained vitamin D. In addition, as most 
patients are only reporting if they are taking a supplement, and not the dosage of 
these, it is difficult to assess the effect properly. Due to this, supplement use was not 
included in the GEE analysis. 
 
Three univariate GEE analyses were conducted to assess changes in 25-OH-D 
(Appendix 4. 2). According to the first univariate analysis, time since surgery was 
significantly associated with increasing 25-OH-D blood levels at 3 and 6 months 
post-LSG, p < 0.001. In the second univariate analysis, overall use of 
supplementation was associated with increasing 25-OH-D blood levels, p < 0.001. 
The third univariate analysis determined that seasonal changes were not 
significantly associated with the changes in 25-OH-D blood levels, p = 0.575.  
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A multivariate GEE analysis was then performed, to determine if the changes 
observed in 25-OH-D could be explained by the time since surgery or the use of 
supplementation. According to the multivariate analysis, time since surgery 
remained significant, p = 0.001, while the overall use of supplementation was no 
longer significantly associated with the increase in 25-OH-D blood values, p = 0.615. 
(Appendix 4.2.) 
In addition, correlation analyses and regression models were performed to 
determine if the doses of vitamin D supplement specifically was associated with 25-
OH-D blood levels. There were no significant associations determined at baseline (r 
=  -0.024, p = 0.912), 3 months (r = 0.167, p = 0.416) or 6 months (r = 0.039, p = 
0.840) post-LSG. 
 
Is there a correlation between weight lost and the change in 25-OH-D levels 
following surgery? 
 
In addition to the seasonal variation analysis for 25-OH-D, a correlational 
analysis was performed for 25-OH-D and weight parameters. In the first analysis, the 
relationship between body weight (kg) and 25-OH-D levels at baseline and at 3 and 
6 months were analyzed. According to the analysis, there were moderate inverse 
correlations between weight (kg) and the levels of 25-OH-D at baseline (r = -0.343, p 
< 0.001), 3 months (r = -0.290, p = 0.01) and 6 months post-LSG (r = -0.295, p – 
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0.012). This indicates that both pre- and post-surgery, the higher the weight of a 
patient, the lower the 25-OH-D blood levels. 
The changes in 25-OH-D levels from baseline to 3 and from baseline to 6 
months were analysed for correlation with the changes in weight from baseline to 3 
and from baseline to 6 months. There was a weak correlation between the weight 
lost and the increase in 25-OH-D from baseline to the 3-month follow-up (r = 0.242, 
p = 0.033). No significant correlation was demonstrated for the changes in weight 
and 25-OH-D from baseline to the 6-month follow-up.
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4.3.2. Hematological parameters 
Table 4. 5  
Changes in the proportion of patients with abnormal values of the parameters associated with hematological status  
 Normal reference  Baseline  
n (%) 




Ferritin M: 24 – 336 μg/L N 95 88 90 
 F: 11 – 307 μg/L Normal 85 (89.5) 77 (87.5) 82 (91.1) 
  High 9 (9.5) 7 (8) 3 (3.3) 
  Low 1 (1.1) 4 (4.5) 5 (5.6) 
Hemoglobin M: 140 – 180 g/L N 95 93 91 
 F: 120 – 160 g/L Normal 84 (88.4) 82 (88.1) 79 (86.8) 
  High 1 (1.1) 1 (1.1) 2 (2.2) 
  Low 10 (10.5) 10 (10.8) 10 (11) 
MCV M: 80 – 97 fL N 95 93 91 
 F: 81 – 99 fL Normal 84 (88.4) 86 (92.5) 83 (91.2) 
  High 2 (2.1) 1 (1.1) 3 (3.3) 
  Low 9 (9.5) 6 (6.4) 5 (5.5) 
Vitamin B12 < 107 pmol/L N 95 87 90 
  Normal 95 (100) 87 (100) 90 (100) 
  Low 0 0 0 
Note: McNemar analysis. n = Number of patients. N = Total number of patients. High = Levels higher than upper reference 
value. Low = Levels lower than lower reference value. Normal = Levels within the normal reference values. F = Female 
patients. Male and female abnormalities are combined for the baseline, 3 and 6 months columns.
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From baseline to 3 and 6 months post-LSG, is there a deterioration of the blood 
values of the hematological parameters; ferritin, hemoglobin, mean cell volume (MCV) 
and vitamin B12 or do they remain stable? 
From baseline to 3 and 6 months post-LSG, is there an increase in the 
proportion of patients with abnormal values of the hematological parameters; ferritin, 
hemoglobin, mean cell volume (MCV) and vitamin B12? 
 
A significant decrease in ferritin levels was observed at 3 and 6 months 
following surgery (p < 0.001) for both male and female patients (Appendix 4.1). The 
decrease in mean levels impacted the proportion of patients with abnormally low 
ferritin. Only one female patient presented with a low ferritin level at baseline, but 
by 3 months post-LSG, four female patients (4.5 %) had developed low levels and by 
6 months post-LSG, five female patients (5.6 %) continued to present with this 
abnormality, p > 0.05 (Table 4.5). In addition to the female patients presenting with 
low ferritin, nine patients (9.5 %) presented with ferritin levels higher than normal 
at baseline, although this proportion decreased post-operatively (p > 0.05).  
The mean hemoglobin values were within the normal reference range pre- 
and post-LSG, and they remained stable throughout the first 6 months following LSG. 
However, 10 patients (10.5 %) presented with low hemoglobin at baseline, 
indicating anemia. There continued to be 10 patients presenting with low 
hemoglobin at the 3 and 6-months follow-ups, although they were not all the same 
109  
patients (Table 4.5.). A very small proportion of female patients presented with 
hemoglobin concentrations higher than the normal reference value (> 160 g/L); 1.1 
%, 1.1 % and 2.2 % at baseline, 3 months and 6 months, respectively (p > 0.05). 
There was an overall significant increase in mean MCV from baseline to 6 
months following LSG (p < 0.001) although mean MCV were within the normal 
ranges for males and females at each time-point. However, nine female patients (9.5 
%) presented with lower than normal MCV at baseline, and a non-significant 
decrease to five female patients (5.5 %) at the 6-month follow-up was observed. In 
addition, two female patients (2.1 %) presented with higher than normal MCV at 
baseline, one patient had high MCV at the 3-month follow-up (1.1 %) and three 
patients (3.3 %) had high MCV at 6 months following LSG, p > 0.05 (Table 4.5). 
The mean values of vitamin B12 varied throughout the study; increasing 
slightly from 359.9 pmol/L at baseline to 366.4 pmol/L at 3 months post-LSG (p > 
0.05), before decreasing significantly to 324.9 pmol/L at 6 months post-LSG (p = 
0.006). Despite these changes, the mean values were within the normal range and 
none of the patients in this study experienced insufficient levels of vitamin B12 (< 
107 pmol/L) at any time-point throughout the study period (Table 4.5). 
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4.5. Parameters associated with NAFLD 
At baseline, 76 patients (80 %) presented with abnormal blood values for one 
or more of the seven biochemical parameters associated with NAFLD. The 
proportion of patients with abnormal liver parameters decreased significantly in the 
follow-up period, with 60 % at 3 months (p < 0.005) and 50.5 % at 6 months (p < 
0.001) post-LSG. The most common abnormalities prior to surgery were elevated 
GGT, 41.9 %, elevated triglycerides, 41.5 %, low HDL, 28.7 % and elevated LDL, 28.3 
% (Table 4.8). 
All mean values of the seven biochemical parameters were within the normal 
reference range both prior to – and following surgery, except for the mean value of 
triglycerides at baseline (1.98 mmol/L), which was slightly above the normal 
reference value of 1.9 mmol/L. 
 
From baseline to 3 and 6 months post-LSG, is there a change in the values of the 
biochemical parameters associated with NAFLD; ALP, ALT, GGT, total bilirubin, HDL, 
LDL and triglycerides? 
From baseline to 3 and 6 months post-LSG, is there a change in the proportion 
of patients with abnormal values of the biochemical parameters associated with 
NAFLD; ALP, ALT, GGT, total bilirubin, HDL, LDL and triglycerides? 
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Table 4. 6  










Bilirubin < 20 μmol/L N 93 94 92 
  Normal 86 (92.5) 87 (92.6) 82 (89.1) 
  High 7 (7.5) 7 (7.4) 10 (10.9) 
ALP < 150 U/L N 93 91 91 
  Normal 93 (100) 91 (100) 91 (100) 
  High 0 0 0 
ALT < 55 U/L N 93 93 90 
  Normal  83 (89.2) 88 (95.7) 90 (100) 
  High 10 (10.8) 4 (4.3) 0* 
GGT < 32 U/L N 93 89 84 
  Normal 54 (58.1) 70 (78.7) 75 (89.3) 
  High 39 (41.9) 19 (21.3)* 9 (10.7)* † 
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HDL > 0.9 mmol/L N 94 93 92 
  Normal 67 (71.3) 70 (75.3) 79 (85.9) 
  Low 27 (28.7) 23 (24.7) 13 (14.1)* † 
LDL < 3.4 mmol/L N 92 93 92 
  Normal 66 (71.7) 74 (79.6) 70 (76.1) 
  High 26 (28.3) 19 (20.4) 22 (23.9) 
Triglycerides < 1.9 mmol/L N 94 93 92 
  Normal 55 (58.5) 82 (88.2) 84 (91.3) 
  High 39 (41.5) 11 (11.8)* 8 (8.7)* 
 
Note: McNemar analysis. n = Number of patients. N = Total number of patients. High = Levels higher than upper reference 
value. Low = Levels lower than lower reference value. Normal = Levels within the normal reference values. * = p-value < 
0.05 when compared to baseline. † = p-value < 0.05 when compared to 3 months.
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Prior to undergoing the LSG procedure, two patients (2.1 %) presented with 
a self-reported diagnosis of NAFLD. The first patient presented with elevated GGT, 
LDL and triglycerides concentrations at baseline, but all parameters were within the 
normal range at the 6-month follow-up. The second patient with self-reported 
NAFLD had elevated GGT, ALT and triglycerides concentrations at baseline along 
with a low concentration of HDL. By the 6-month follow-up, all pre-existing 
abnormalities had resolved, except for a continuously low HDL.  
 
The mean value of bilirubin increased significantly throughout the study from 
12.2 μmol/L at baseline, to 13.2 μmol/L at 6 months post-LSG, p = 0.008 (Appendix 
4.1). The proportion of patients with elevated bilirubin values (> 20 μmol/L) 
increased as well post-operatively from 7.5 % at baseline to 10.9 % at 6 months 
following surgery (p > 0.05). There was a modest, but non-significant, decrease in 
ALP levels in the follow-up period, however no ALP abnormalities were observed at 
any time-point through the duration of the study (Table 4.6). 
ALT is one of the most common liver indicators measured and 10.8 % of the 
patients presented with elevated ALT levels (> 55 U/L) at baseline. There was a 
significant improvement post-operatively, as all patients experienced a resolution of 
their pre-existing ALT-abnormality by the 6-month follow-up, p = 0.002 (Table 4.6). 
This is supported by the significant decrease in mean ALT blood levels from 31.5 
U/L at baseline to 18.1 U/L at 6 months post-LSG (p < 0.001). 
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A significant decrease was also observed for GGT, which decreased from 62 
U/L at baseline to 23.9 U/L at 3 months, p < 0.001 and 21.4 U/L at 6 months post-
LSG, p < 0.001 (Appendix 4.1). This was the most common abnormality prior to 
surgery, with 39 patients (41.9 %) presented with GGT levels above the normal 
reference (> 32 U/L), and there was a significant reduction in the proportion of 
patients with this GGT abnormality by 6 months, with only 10.7 % of patients, p < 
0.001 (Table 4.6). 
Despite a minor, non-significant decrease in the mean value of HDL at 3 
months post-LSG, there was a significant increase from 1.04 mmol/L at baseline to 
1.12 mmol/L at 6 months following LSG (p < 0.001). 28.7 % of patients experienced 
lower than normal HDL (< 0.9 mmol/L) prior to undergoing surgery. While the 
mean value of HDL had increased by 6 months post-LSG, the proportion of patients 
with low HDL had significantly decreased to 14.1 % (p = 0.007).  
The mean values of LDL fluctuated post-operatively, with a significant 
decrease from 2.85 at baseline to 2.61 at 3 months post-LSG (p = 0.006) and then a 
significant increase to 2.79 mmol/L at 6 months post-LSG (p = 0.008). A large 
proportion of patients (28.3 %) presented with LDL values higher than normal (> 
3.4 mmol/L) at baseline. There was a non-significant decrease by 3 months post-
LSG, where 20.4 % of patients had high LDL, before a slight increase to 23.9 % was 
observed at the 6-month follow-up, p > 0.05 (Table 4.6). 
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There was a significant decrease in the mean levels of triglycerides 
throughout the study from 1.98 mmol/L at baseline to 1.42 and 1.33 mmol/L at 3 
and 6 months post-LSG, respectively, p < 0.001 (Appendix 4.1). The mean level at 
baseline was the only mean blood value of the biochemical parameters associated 
with NAFLD outside the normal reference range, and 41.5 % of patients in this study 
experienced a higher than normal triglyceride level (> 1.9 mmol/L) prior to 
undergoing LSG. The majority experienced an improvement, as there was a 
significant decrease in the proportion of patients with elevated triglycerides levels 
at 3 (11.8 %) and 6 months (8.7 %) post-LSG, p < 0.001 (Table 4.6). 
 
As previously mentioned, two studies proposed methods to more accurately 
predict the absence or presence of NALFD (Bedogni et al., 2006; Borman et al., 
2013). Based on these methods, both the Fatty Liver Index (FLI) and the Steatosis 
Index (SI) were calculated for this patient sample (Table 4.7). Because waist 
circumference wasn’t obtained as standard procedure at the beginning of the study, 
only 65 patients had the information required for the calculation of the FLI at 
baseline. In the algorithm for the FLI, the triglycerides is measured in mg/dL, 
however the triglycerides unit measured in the current study is mmol/L. Therefore, 
before calculating the FLI, the triglycerides values obtained were converted into 
mg/dL, by multiplying the values by 88. 57396. 
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Table 4. 7  
Fatty Liver Index and Steatosis Index for the sample population 
 Fatty Liver Index Steatosis Index 
 Baseline  
(n = 65) 
3 months  
(n = 84) 
6 months  
(n = 75) 
Baseline  
(n = 91) 
3 months  
(n = 88) 
6 months  
(n = 86) 
Mean  SD 99.16  1.30 90.14  13.30* 82.80  19.13*† 0.96  0.04 0.88  0.11* 0.82  0.13*† 
Median 99.75 96.07 89.97 0.97 0.91 0.84 
Min – Max 93.34 – 99.99  37.39 – 99.93 17.34 – 99.93 0.81 – 1.0 0.47 – 0.99 0.48 – 0.99 
25th and 75th 
Quartiles 
98.90 – 99.92 86.63 – 99.00 72.78 – 97.41 0.94 – 0.99 0.84 – 0.95 0.75 – 0.93 
Note: Repeated measures ANOVA/Friedman’s with Wilcoxon’s. * = p-value < 0.05 when compared to baseline. † = p-value 
< 0.05 when compared to 3 months. (n) = total number of patients with available data for each time point.  
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A FLI > 60 would, according to the author (Bedogni et al. 2006), suggest the 
presence of fatty liver, while a FLI < 30 would indicate the absence. At baseline, all 
patients presented with a FLI > 60, indicating that all patients had fatty liver. A slight 
improvement was observed at 3 months, with 96.4 % of patients having a FLI > 60. 
At the 6 month follow-up, a significant improvement was observed, as 88 % of 
patients continued to present with a FLI > 60 while 2 patients (2.7 %) now 
presented with a FLI < 30, indicating the absence of fatty liver disease (p-value < 
0.05).  
The study by Borman et al. (2013) did not provide any cut-off to use with the 
SI, as it has yet to be validated against other indexes. Due to this, it was not possible 
to determine the proportion of patients with NAFLD according to the SI. However, a 
correlation analysis was performed for the FLI and the SI to determine if there was a 
relationship between the two indexes. Based on the scatterplots and analyses, there 
was a moderate positive correlation between the FLI and the SI at baseline (r = 
0.7611, p < 0.001), as well as a strong correlation at 3 months (r = 0.810, p < 0.001) 







4.5.1. Weight correlation 
Is there a correlation between weight lost and the change in the biochemical 
parameters associated with NAFLD following surgery? 
 
Univariate correlation analysis was conducted to determine any significant 
relationships between weight parameters and the select biochemical parameters 
associated with NAFLD. The first set of analysis assessed the correlation between 
body weight (kg) at baseline, 3 and 6 months post-LSG, along with the 
corresponding blood values of the seven biochemical parameters.  
Significant inverse correlations between body weight and HDL levels were 
demonstrated for baseline (r = -0.230, p = 0.026), 3 months (r = -0.307, p = 0.003) 
and 6 months post-LSG (r = -0.342, p < 0.001). This indicates that as weight 
decreased, the HDL levels increased. In addition, a weak correlation between 
baseline weight and bilirubin levels (r – 0.296, p = 0.004), along with a significant 
correlation between the 6 months weight and GGT levels (r = 0.252, p = 0.023) were 
observed. The second set of correlation analysis was done for the change in body 
weight and the changes in the biochemical parameters. The only significant findings 
were modest correlations for the weight lost and the decrease in triglyceride levels 
from baseline to 3 months (r = 0.238, p = 0.023) and from baseline to 6 months post-
LSG (r = 0.237, p = 0.026). This suggests that the greater the weight loss, the greater 




One of the main findings in this study was a significant increase in 25-OH-D at 
both 3 and 6 months following LSG. Although time since surgery is likely to explain 
the increase observed, a possible benefit from supplement use cannot be ruled out. 
In addition, significant improvements in the majority of biochemical parameters 
associated with NAFLD were observed in the follow-up period. This was supported 
by the significant improvements observed in the Fatty Liver Index as well as the 
Steatosis Index. 
 
5.1. Demographic profile 
The current study sample had a mean BMI of 49.3 kg/m2, which was similar 
to the mean BMI of 49.7 kg/m2 found in the other studies identified on this area of 
research (Aarts et al., 2011; Damms-Machado et al., 2012; Gehrer et al., 2010; 
Hakeam et al., 2009; Kehagias et al., 201; Moize et al., 2012; van Rutte et al., 2014; 
Ruiz-Tovar et al., 2012). The baseline demographics of the current study sample 
were also similar to the baseline demographics found in those studies in regards to 
age (49.95 ± 10.8 years) and the distribution of comorbidities. The most common co-
morbidities in these studies were dyslipidemia, hypertension and type 2 diabetes, 
similar to the common co-morbidities found in the current study. However, a larger 
proportion of this study sample was female (80.3 %) when compared to the 
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proportion of female patients found in the other studies (61.3 %), while the baseline 
weight (135.7 ± 25.3) was lower than the baseline weight among these other studies 
(142.3 ± 23.6). 
In a study by Padwal et al. (2012), the demographic profiles of patients 
eligible for bariatric surgery in Canada were determined and compared with the 
patients actually receiving surgery. They found that patients receiving bariatric 
surgery were younger (43.6 vs. 45.8 years) and had a lower prevalence of 
comorbidities such as hypertension (13.1 % vs. 39.2 %), type 2 diabetes (2.4 % vs. 
15.1 %) and dyslipidemia (21.1 % vs. 63.1 %) than patients eligible, but not 
receiving bariatric surgery.  
The baseline demographic profile of patients in the current study sample is 
similar to patients receiving bariatric surgery in Canada for age and the percentage 
of female patients (44.9 vs. 43.6 years and 82.1 % vs. 82 %, respectively). However, 
the prevalence rates of comorbidities in the current study were much higher than 
patients in general receiving bariatric surgery in Canada for sleep apnea, 
dyslipidemia, hypertension, type 2 diabetes and coronary heart disease; 63.9 % vs. 
10.9 %, 58.7 % vs. 2.4 %, 51.1 % vs. 13.1 %, 35.1 % vs. 21.1 % and 5.3 % vs. 0.9 %, 
respectively (Padwal et al., 2012). It is important to note, that these demographic 
characteristics are only for the 95 patients who, at the time of writing this thesis, had 
completed their baseline, 3 months and 6 months post-LSG assessments.  
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5.2. Changes in micronutrients and related parameters  
All patients had their blood work done 1 to 2 days prior to undergoing 
surgery and this constitutes the baseline values. However, it is important to keep in 
mind, that these values are representative of the micronutrient status after the 
patients attended the orientation and completed the full-fluid diet. The full-fluid diet 
is likely to have improved patient’s micronutrient status at baseline, as they were 
instructed to follow a strict diet prior to surgery. Due to this, the baseline values 
might be a slight underestimate of the actual micronutrient status in patients 
seeking bariatric surgery in Newfoundland & Labrador in general.  
The overall mean blood values were within the normal reference for all 
variables both at baseline and at the 3 and 6-month follow-ups, except for the mean 
PTH value at 3-months post-LSG. Despite this, patients presented with abnormal 
blood values for one or more of the micronutrient-related parameters measured at 
each time-point. The majority of patients (57.7 %) presented with a micronutrient-
related abnormality prior to surgery. This prevalence rate is almost identical to the 
findings by Gehrer et al. (2010) where 57 % presented with a baseline abnormality, 
and similar to the baseline prevalence of 51 % found by Damms-Machado et al. 
(2012). The 11 studies identified do not provide an overall estimate of the 
proportion of patients with one or more abnormality at each follow-up, so it is not 
possible to compare the prevalence rates of 52.1 % and 42.3 % (3 and 6 months, 
respectively) found in the current study to any other results reported. 
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5.2.1. Bone health parameters 
Elevated levels of PTH (26.9 %) and low levels for 25-OH-D (21.3 %) were 
the most commonly found abnormalities in the current study, and consistent with 
other studies where elevated PTH and low 25-OH-D were the most commonly 
observed abnormalities prior to and after LSG. The prevalence of low vitamin D/25-
OH-D in the studies assessing this parameter, ranges from 23 % to 96.7 % at 
baseline, (Gehrer et al., 2010; Ruiz-Tovar et al., 2012), but with the majority 
reporting a prevalence rate in the 75th quartile (Damms-Machado et al., 2012; Moize 
et al., 2012; Saif et al., 2012; van Rutte et al., 2014).  
In regards to 25-OH-D, patients in the current study appear to be well 
managed prior to surgery, with the majority having sufficient levels despite the fact 
that only 27.7 % were taking a specific vitamin D supplement. The prevalence rate of 
low 25-OH-D among the current study sample (21.3 %) was considerably lower than 
the national rate ( 32 %), but the mean baseline level of 69.6 nmol/L was similar to 
the estimated mean level of 63.5 nmol/L from the general population [Janz & 
Pearson, 2013, Statistics Canada (b), 2013]. In addition, the large proportion of 
patients with sufficient 25-OH-D levels (78.7 %) in the current study, is in contrast 
to the otherwise high prevalence of 25-OH-D deficiency in the general Canadian 
population, especially in Newfoundland & Labrador [Janz & Pearson, 2013; 
Newhook et al., 2009; Statistics Canada (b), 2013].  
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The bariatric patients might have been aware of this increased risk in the 
province, and could have sought out preventative options prior to seeking bariatric 
surgery, thus presenting with overall sufficient blood levels. According to the 2009-
2011 Canadian Health Measures Survey (CHMS), Cycle 2, an estimated 32 % of all 
Canadians had 25-OH-D blood levels below 50 nmol/L. However, it might also be 
due to the 25-OH-D analysis used at the Health Sciences Centre. This in-house 
developed assay provides slightly higher values that the radioimmunoassays 
typically used at other sites and in most clinical studies (Hollis, 2012; Personal 
correspondence with Dr. Edward Randell).  
The 21.3 % prevalence rate of low 25-OH-D in the current study, is similar to 
the findings by Gehrer et al. (2010), where 23 % of the patients presented with low 
25-OH-D prior to undergoing LSG. In that study however, there was an increase in 
the proportion of patients with low 25-OH-D in the follow-up period, whereas a 
significant reduction was observed at 6 months post-LSG in the current study, with 
only one patient presenting with low 25-OH-D. A similar finding was observed by 
Ruiz-Tovar et al. (2012), where the 96.7 % prevalence rate at baseline was reduced 
to 13.2 % at 3 months post-LSG (11.4 % at 3 months post-LSG in the current study) 
and a further reduction to just one patient at the 6-month follow-up. The majority of 
the other studies assessing the changes in 25-OH-D following LSG, reported 
improvements in the follow-up period, although the prevalence rates of low 25-OH-
D post-LSG ranged from 34.3 % to 77.2 % (Damms-Machado et al., 2012, Moize et al., 
2013; Saif et al., 2012; van Rutte et al., 2014).  
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25-OH-D blood concentrations vary by seasons, as vitamin D is synthesized in 
the skin due to sun exposure. Mean concentrations of 25-OH-D are typically higher 
in summer when compared to winter, and differences in mean values ranges from 
15.1 % to 35.2 % (Gozdzik et al., 2009; Newhook et al., 2009; Ross et al., 2011). The 
2011 report on vitamin D from the Institute of Medicine, which analyzed multiple 
studies, reported a variation in mean 25-OH-D values of 25 nmol/L from winter to 
summer (Ross et al., 2011). According to the CHMS, Cycle 2, there is a difference of 
37.5 % between individuals with insufficient 25-OH-D concentrations, and a 
difference of 60 % between individuals with deficient 25-OH-D concentrations when 
comparing summer to winter (Janz & Pearson, 2013).  
However, the seasonal variations for 25-OH-D concentrations were not 
significantly different at any time in the current study, which was determined by two 
separate analyses. The reason for the non-significant variation of mean 25-OH-D 
concentrations may be due to a small sample size or the fact that nearly all patients 
were taking supplements following LSG. In the other studies assessing 25-OH-D 
following LSG, none mention seasonal variations or whether their results were 





Elevated PTH were the most prevalent abnormality observed in patients 
prior to surgery with 26.9 % of patients presenting with higher than normal levels. 
Other studies have reported elevated PTH as being one of the most common 
abnormalities prior to surgery as well, with prevalence rates ranging from 6.7 to 
62.5 % (Gehrer et al. 2010; Kehagias et al., 2011; Moize et al., 2013; Ruiz-Tovar et al., 
2012; Saif et al., 2012; van Rutte et al., 2014). An initial significant increase in mean 
PTH was observed 3 months post-LSG, which resulted in an increase in the 
proportion of patients with elevated PTH in the same time-period (38.2 %), although 
this was not statistically significant. At the 6-month follow-up, a slight decrease in 
mean PTH and a corresponding decrease in the proportion of patients with elevated 
PTH (36.8 %) were observed. Only the study by Gehrer et al. (2010) reported an 
increase in the proportion of patients with elevated PTH levels, from 8 % at baseline 
to 14 % post-operatively. The other studies all reported improvements in PTH 
following LSG, with the prevalence rates for elevated PTH ranging from 0 % to 40.9 
% (Kehagias et al., 2011; Moize et al., 2013; Ruiz-Tovar et al., 2012; Saif et al., 2012; 
van Rutte et al., 2014). 
 
The initial unexpected increase in the proportion of patients with elevated 
PTH observed in this study, could be due to several factors. Usually when PTH levels 
are elevated, one would examine the 25-OH-D, to determine if the elevated PTH 
levels are due to insufficient 25-OH-D and thereby low calcium intake and decreased 
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post-operative absorption. But because the mean 25-OH-D levels were normal, the 
increase in PTH elevation cannot be attributed to reduced calcium absorption in 
some patients. Another possible explanation specific to this study, is related to 
technical issues with the assay used for the PTH analysis. The laboratory at the 
Health Sciences Centre in St. John’s, Newfoundland, had been made aware by the 
manufacturer, that the assay might be malfunctioning, as shown by an upward drift 
in the reading of high control values. The manufacturer temporarily removed the 
assay from the market, but the issue has now been resolved. Although falsely 
elevated values were never detected at the main laboratory site connected to this 
study, it is possible that the assay contributed to the unexpected increasing 
prevalence of elevated PTH observed 3 months following LSG.  
Due to difference in laboratory protocols, measurements for 25-OH-D and 
PTH were not part of standard blood work routine, and had to be ordered specially 
for the research study. This resulted in a decrease in the number of patients with 25-
OH-D and PTH assessments completed in the follow-up periods. Measurements for 
25-OH-D decreased from 94 completed assessments at baseline, to 79 and 69 
assessments at 3 and 6 months post-LSG, respectively. The number of patients with 
complete PTH assessments decreased from 93 at baseline to 89 and 87 patients at 3 
and 6 months, respectively. Because of this decrease, the results for 25-OH-D and 
PTH should be interpreted with caution, as the actual results might be slightly 
different if all patients had their 25-OH-D and PTH assessed properly pre- and post-
LSG. 
127  
There was a modest, yet significant increase in albumin-corrected calcium 
concentrations from the 3-month follow-up to the 6-month follow-up, increasing 
from 2.43 mmol/L at baseline to 2.46 mmol/L. Only a few patients presented with 
higher than normal calcium concentrations throughout the course of the study, with 
fluctuating changes post-operatively. Calcium abnormalities are not very prevalent 
in patients prior to or following LSG, and while some of the other studies have 
reported a few patients presenting with low calcium concentrations, none have 
reported patients experiencing higher than normal calcium concentrations (Aarts et 
al., 2010; Capoccia et al., 2012; Damms-Machado et al., 2012; Gehrer et al., 2010; 
Kehagias et al., 2011; Moize et al., 2013; Ruiz-Tovar et al., 2012; Saif et al., 2012, van 
Rutte et al., 2014). Even though a significant increase in mean calcium was observed 
post-LSG in the current study, the slight increase in proportion of patients with high 
calcium concentrations at the 6-month follow-up (1.1 % to 4.5 %) was not 
statistically significant.  
 
In summary, the proportion of patients with low 25-OH-D and elevated PTH 
were lower than the proportions found in other studies. 25-OH-D and PTH 
constitute the majority of the micronutrient-related abnormalities observed in the 
current study, which is similar to that reported by others (Damms-Machado et al., 
2012; Moize et al., 2012; Ruiz-Tovar et al., 2012; Saif et al., 2012; van Rutte et al., 
2014). There was a significant reduction in the proportion of patients with lower 
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than normal 25-OH-D post-LSG, which is consistent with the majority of other 
studies assessing 25-OH-D following LSG. An initial, non-significant increase in the 
proportion of patients with elevated PTH was observed in the follow-up period, 
which is in contrast to findings reported by other studies, where improvements in 
PTH is typically observed post-LSG. However, this increase in elevated PTH 
prevalence may be due to technical issues with the assay used for analysis.  
As hypothesized, a significant improvements in 25-OH-D were observed 
following LSG in the current study, both in regards to the biochemical changes and 
the proportional changes. However, the findings regarding the change in PTH 
following LSG are inconsistent with the hypothesis of an improvement in PTH post-
LSG, as both improvements and deteriorations were observed. In addition, the 
increase in calcium blood levels was consistent with the hypothesis.  
 
5.2.1.1. Weight parameter correlations 
The current study demonstrated a moderate, inverse correlation between the 
baseline weight of the study sample and their corresponding levels of 25-OH-D both 
pre- and post-LSG. This significant relationship indicates that patients with a higher 
baseline body weight had significantly lower levels of 25-OH-D. This relationship 
between weight parameters (e.g. BMI, total body weight, body fat) and 25-OH-D 
blood levels, has been observed by others as well (Ruxton, 2011). The present study 
also demonstrated a moderate inverse correlation between weight loss and 25-OH-D 
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increase in the first 3 months following LSG. This finding is similar to that found by 
Ruiz-Tovar et al. (2012) who also reported a significant inverse correlation between 
the weight lost and the increase in 25-OH-D levels observed after the first 3 months 
of follow-up.  
The relationship between weight loss and 25-OH-D increase observed in the 
current study could further support the theory that the amount of 25-OH-D 
sequestered in adipose tissue is reduced following LSG. However, it remains unclear 
whether the increase in 25-OH-D levels observed is due to a release of stored 25-OH-
D, a reduction in the amount stored before reaching the liver, or increased 




Studies suggest that the use of supplementation is an important factor in 
post-operative care, and that the use should be supervised closely in order to 
prevent deficient or toxic concentrations of any micronutrient (Aarts et al., 2011; 
Capoccia et al., 2012; Damms-Machado et al., 2012; Gehrer et al., 2010; Saif et al., 
2012). Despite patients not being provided a uniform supplement by the bariatric 
surgery clinic, more than half of the study sample (55.3 %) was taking one or more 
supplements prior to surgery, and nearly all patients reporting using supplements in 
the follow-up period, the most common being a multivitamin. In addition, there did 
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appear to be a relationship between the use of supplementation and the prevalence 
of low 25-OH-D levels, as the overall use of supplements increased while the 
prevalence of low 25-OH-D decreased in the follow-up period.  
 
The effect of supplementation has been examined in several studies 
examining micronutrient-related changes following LSG, but there is currently no 
consensus on the magnitude of this potential effect. Two studies report that the use 
of supplementation did not have an effect on the blood values of the specific 
micronutrient-related parameters measured (i.e. 25-OH-D, vitamin B12, calcium, 
PTH), and when supplemented patients were compared to those not supplemented, 
no significant differences were observed (Damms-Machado et al., 2012; Saif et al., 
2012).  
Two other studies by Capoccia et al. (2012) and Gehrer et al. (2010) however, 
reported a positive effect from supplement use, although the micronutrient-related 
parameters impacted varied within the studies (i.e. vitamin D/25-OH-D, vitamin B12, 
calcium, PTH). Gehrer et al. (2010) also reported that any newly developed 25-OH-D 
deficiencies following LSG could be treated with supplementation in 100 % of the 
patients. There continues to be some inconsistencies regarding the effect of 
supplementation on the prevalence of low 25-OH-D levels. Despite the positive effect 
observed by Gehrer et al. (2010), the study by Capoccia et al. (2012) reported 
continuously low 25-OH-D levels throughout the study despite the use of 
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supplementation. Damms-Machado et al. (2012) reported a significant difference in 
the proportion of patients with low 25-OH-D levels, with the majority not being 
supplemented. However, the reported p-value was 0.049, indicating borderline 
significance.  
All information on supplement usage was self-reported, and the majority of 
patients reported if they were using a supplement, but not the type of supplement or 
dose. It was possible to ascertain the dose of the vitamin D supplements based on 
each patient’s medication profile. However, as the majority of patients were also 
taking a multivitamin or other supplement (e.g. calcium, some of which likely 
contain vitamin D), therefore, it was not possible to provide an accurate assessment 
of total consumption of vitamin D. The dose of vitamin D supplement alone could 
potentially underestimate the actual effect of supplement use on 25-OH-D levels.  
The overall use of supplementation was significantly associated with the 
increase in 25-OH-D in the univariate GEE analysis, however it was not significant in 
the multivariate model. This suggests other factors such as dietary assessment and 
estimates of sun exposure, not assessed in the current study, may play an important 
role in impacting 2-OH-D blood levels.   Despite an increase in the use of 
supplementation, patients continued to present with low 25-OH-D levels.  
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5.2.3. Hematological parameters 
Abnormalities in the select hematological parameters were more prevalent 
among the female patients, which is expected, as they constituted the vast majority 
of the study sample and more significant blood loss occurs among pre-menopausal 
women (Hakeam et al., 2009). A significant decrease in mean ferritin concentrations, 
with a corresponding decrease in proportion of patients with high ferritin 
concentrations, was observed in the current study. However, as six patients 
experience a resolution of their pre-existing high ferritin, four other patients 
developed ferritin concentrations below the normal reference values.  
A possible explanation for the proportion of patients with high ferritin prior 
to surgery, might be due to the fact that ferritin is also an acute inflammation 
indicator (Berkhan, 2002; Shifflet & Wum, 2009; Swaminathan, 2011). Several 
reports suggest that obesity causes a low-grade inflammatory response, which in 
turn can cause ferritin to increase (Lumeng & Saltiel, 2011; Emanuela et al., 2012). 
The improvements in patients’ BMI following LSG in the current study, could 
improve the inflammation state and thus explain the decrease in the proportion of 
patients with high ferritin.  
None of the studies identified in this area of research reported patients 
presenting with higher than normal ferritin concentrations, and just three reported 
increases in the proportion of patients with low ferritin in the follow-up periods 
(Kehagias et al., 2011; Saif et al., 2012; van Rutte et al., 2014). Of the three studies 
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presenting their findings at 6 months post-LSG, none observed abnormal ferritin 
concentrations (Hakeam et al., 2009; Moize et al., 2012; Ruiz-Tovar et al., 2012). The 
actual impact of LSG on ferritin is difficult to assess based on the current study, as 
both improvements and deteriorations were observed in the follow-up period.  
 
10.5 % of patients in the current study presented with low hemoglobin levels 
at baseline, which is identical to the findings by Moize et al. (2012). They reported an 
increase to 12.1 % at 6 months post-LSG, which is similar to the 11 % found in the 
current study. The majority of studies examining changes in hemoglobin following 
LSG, reported an increase in the proportion of patients with low hemoglobin levels 
post-operatively, ranging from 0 to 13.3 % at baseline to 6.5 to 26 % post-LSG (Aarts 
et al., 2011; Hakeam et al., 2009; Kehagias et al., 2011; Moize et al., 2012, van Rutte 
et al., 2014). In the current study, one female patient presented with a hemoglobin 
level higher than normal at baseline and 3 months post-LSG, and at the 6-month 
follow-up two female patients had reportedly high hemoglobin levels. Elevated 
hemoglobin could be caused by dehydration, which can occur following bariatric 
surgery, as the fluid intake is reduced due to the small stomach size. None of the 




MCV is not commonly measured in studies on micronutrient-related changes 
following LSG, and not many baseline findings from other studies are available for 
comparison to the findings from the current study. In our study, nine female patients 
(9.5 %) presented with low MCV, followed by a non-significant decrease to five 
female patients (5.5 %) at the 6-month follow-up. The studies by Aarts et al. (2011) 
and van Rutte et al. (2014) presented the proportion of patients with abnormal MCV 
pre- and post-LSG. Their findings showed a baseline prevalence of low MCV at 5 %, 
however one study reported an increasing prevalence to 15 % post-LSG (Aarts et al., 
2011) while the other study reported a decrease in the proportion of patients with 
low MCV to 2 % (van Rutte et al., 2014).  
In the study by Hakeam et al. (2009), low MCV was used as an exclusion 
criterion, thus ensuring a 0 % prevalence rate for MCV abnormalities at baseline. At 
the 6-month follow-up, two patients (3.2 %) in that study presented with low MCV. 
Hakeam et al. (2009) also reported decreasing MCV in the follow-up period, which is 
in contrast to the current study, where significantly increasing MCV was observed 
post-LSG. In addition, a couple of female patients continued to present with MCV 
above the normal reference value throughout the study, which has not been 




Low levels of vitamin B12 is one of the most commonly found abnormalities 
prior to and after bariatric surgery. One of the possible causes post-operatively may 
be related to the fact that as the majority of the gastric pouch being removed during 
LSG, less intrinsic factor and hydrochloric acid will be produced and available post-
operatively. These factors are necessary for the absorption of vitamin B12, thus 
abnormal blood levels of this vitamin is likely to be observed following LSG due to a 
reduced absorption (Hakeam et al., 2009; Rickers & McSherry, 2012; Snyder-Marlow 
et al., 2010, van Rutte et al., 2014). In the current study though, no patients 
presented with insufficient levels of vitamin B12 at any time-point throughout the 
study. Only one other study reported all patients presenting with sufficient vitamin 
B12 levels throughout the study (Ruiz-Tovar et al., 2012), while the remaining 
studies reported a prevalence rate for vitamin B12 abnormalities between 2.7 % and 
9.3 % at baseline (Damms-Machado et al., 2012; Gehrer et al., 2010; Hakeam et al., 
2009; Kehagias et al., 2011; Moize et al., 2012, van Rutte et al., 2014). These studies 
all reported a consistent increase in the proportion of patients with low vitamin B12, 
to as much as 19.6 % at 6 months post-LSG (Hakeam et al., 2009). 
No patients presented with a vitamin B12 abnormality in the current study, 
despite the fact that the vast majority of patients (> 87 %) did not receive any 
vitamin B12 supplementation. However, as most multivitamins contain a wide range 
of vitamins and minerals, including vitamin D, calcium, iron and vitamin B12, and the 
majority of patients in the current study were taking a multivitamin pre and post-
LSG, supplement use could be a reason for the sufficient vitamin B12 levels observed 
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(Zelman, 2011). Another possible explanation for the absence of any vitamin B12 
abnormalities post-LSG, is the storage of this vitamin in the tissue. Usually the 
storage will contain enough vitamin B12 to ensure sufficient blood levels for years 
before an abnormality will present (Koch & Finelli, 2010; Lovette et al., 2012). 
 
In summary, one of the more important findings regarding the hematological 
parameters was that no patients presented with low vitamin B12 levels at any time-
point, as this is otherwise a commonly found abnormality observed pre- and post-
LSG. As with the other studies assessing hematological parameters following LSG, 
only a small percentage of patients (< 10 %) experienced low ferritin and MCV. 
Some patients experienced values above the normal reference values for ferritin, 
hemoglobin and MCV, which have not been reported in other studies. Ferritin blood 
levels decreased, hemoglobin values remained stable, MCV increased and vitamin 
B12 levels fluctuated following LSG, but there were no significant changes in the 
prevalence of abnormalities.  
In contrast to what was anticipated, no deterioration in vitamin B12 was 
observed following LSG. The blood levels of hemoglobin remained stable and no 
significant changes was observed, which is consistent with the hypothesis. Increases 
in MCV was observed post-LSG, which is in contrast to the hypothesis, along with the 
overall decrease in MCV abnormalities. The overall changes of ferritin were 
fluctuating, which is somewhat consisting with the hypothesis. 
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5.3. Non-alcoholic fatty liver disease 
Only two patients (2.1 %) in the study sample presented with a self-reported 
NAFLD diagnosis prior to undergoing LSG. This is far less than the prevalence rates 
generally reported for the overweight and obese population. One study reported as 
many as 34.5 % of patients presented with steatosis (NAFLD) prior to undergoing 
LSG (Karcz et al., 2010), while the prevalence rate in the general obese population is 
as high as 75 – 80 % (Kopec & Burns, 2011; Mahaling et al., 2013; Paschos & Paletas, 
2009). One of the possible explanations for this low prevalence rate observed in the 
current study, could be that the majority of NAFLD patients are asymptomatic and 
are therefore not yet diagnosed (Mishra & Younossi, 2012; Schattenberg & 
Schuppan, 2011; Shifflet & Wu, 2009).  
This theory is supported by the large proportion of patients actually 
presenting with abnormal blood values for one or more of the biochemical 
parameters associated with NAFLD. The vast majority of patients (80 %) 
experienced abnormal blood values prior to surgery, suggesting the actual 
prevalence rate of NAFLD among the patients might be higher than the 2.1 %. Also, a 
study by Chisholm et al. (2012) investigated certain biochemical parameters in a 
group of bariatric patients undergoing laparoscopic gastric banding (LGB), and 
compared the biochemical values between patients with or without NASH. The 
values of the biochemical parameters were significantly higher among the NASH 
patients for GGT, ALT, bilirubin, triglycerides and lower for HDL.  
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Many patients in the current study experienced an improvement or 
resolution of their pre-existing abnormalities following LSG, with a significant 
reduction in the proportion of patients with abnormal blood values at 3 months (60 
%) and 6 months (50.5 %) post-LSG. The most commonly abnormalities related to 
NAFLD, were elevated concentrations of GGT, triglycerides, LDL and ALT along with 
low concentrations of HDL, which is similar to findings reported by other studies 
(Chalasani et al., 2012; Chisholm et al., 2012; Franzini et al., 2011).  
 
ALT is one of the most commonly assessed liver enzymes and studies have 
shown that it is often increased in obese patients seeking bariatric surgery 
(Chisholm et al., 2012; Franzini et al., 2011). In the current study, 10.8 % of patients 
presented with levels above the normal reference range for ALT at baseline, but 
there was a significant improvement as no patients experienced this abnormality at 
the 6-month follow-up. This is consistent with the results reported by Mattar et al. 
(2005), who assessed the ALT values after three bariatric procedures, one of them 
being LSG. They observed a significant decrease in ALT post-surgery, although they 
did not elaborate on the specific results for each procedure.  
GTT levels above the normal reference was the most common abnormality of 
the biochemical parameters associated with NAFLD reported in the current study. 
41.9 % of the patients presented with high GGT levels at baseline, but the majority 
experienced a significant improvement as only 10.7 % continued to have high GGT at 
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the 6-month follow-up. A significant decrease in mean GGT level, from 36.2 U/L at 
baseline to 21.4 U/L at the 6-month follow-up, was also observed in the current 
study, which is similar to finding reported by Ghaemi et al. (2013). However, this 
significant decrease in mean GGT level reported in that study, was observed after 
patients experienced significant weight loss due to micronutrient interventions, not 
bariatric surgery. Fatty liver disease due to alcohol consumption is often associated 
with elevated GGT levels accompanied with normal ALT levels, which was not 
observed in the current study. 
Only a small proportion of study subjects experienced elevated bilirubin at 
baseline (7.5 %), but due to a significantly increased mean blood concentration, 
there was a non-significant increase to 10.9 % at 6 months post-LSG. Similar results 
for bilirubin following LSG have not been reported elsewhere. In addition no 
significant changes in ALP mean values were observed post-operatively, and none of 
the patients in the study sample presented with elevated ALP at any time-point. 
 
Abnormal lipid concentrations were common among the current study 
sample, with high triglyceride levels being the most prevalent pre-LSG (41.5 %). 
Abnormal LDL and HDL levels were also highly prevalent at baseline, with 28.3 % 
and 28.7 % of the patients, respectively. All mean blood values were within the 
normal reference values throughout the study, except for the mean triglyceride level 
at baseline (1.98 mmol/L).  
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A significant increase in HDL levels and a significant decrease in triglycerides 
levels were observed in the follow-up period in the current study. This is consistent 
with the findings by Mattar et al. (2005), who also reported improvement in the 
lipid profile following bariatric surgery. The improvements in blood values observed 
in the current study, corresponded with significant decrease in the proportion of 
patients with abnormal HDL and triglycerides values from baseline to 6 months 
post-LSG (28.7 % to 14.1 % and 41.5 % to 8.7 %, respectively) Mattar et al. (2005) 
reported similar findings, where the improvements in blood values in that study, 
resulted in decreased proportion of patients with abnormal lipids, although the 
differences from baseline to the follow-ups were only significant for triglycerides.  
The levels of LDL fluctuated in the follow-up period. There was a significant 
decrease from 2.85 mmol/L at baseline to 2.61 mmol/L at 3 months post-LSG, with a 
non-significant decrease in the proportion of patients with high LDL from 28.3 % to 
20.4 %. This is consistent with the studies by Ghaemi et al. (2013) and Mattar et al. 
(2005), who both reported significant decreases in mean LDL levels following 
bariatric surgery. However, a significant increase in mean LDL level was observed at 
the 6-month follow-up in the current study, with the proportion of patients with 




Studies have examined the relationship between the status of the parameters 
associated with NAFLD and the severity of NAFLD and/or NASH. They found that 
patients with NAFLD or NASH in general have significantly higher blood levels of 
ALT, GGT and triglycerides as well as significantly lower levels of HDL (Chisholm et 
al., 2012; Franzini et al., 2011). The studies conducted by Razavizade et al. (2012) 
and Mahaling et al. (2013) reported that the levels of LDL, triglycerides and ALT 
decreased while the levels of HDL increased, as the severity NAFLD or NASH 
intensified. In addition, one of the studies also showed that a significantly higher 
proportion of patients presented with liver enzyme or lipid abnormalities when the 
severity of NAFLD or NASH was greater (Mahaling et al., 2013). 
As mentioned earlier, the improvement of these biochemical parameters 
alone is not a reliable tool in the diagnosis or estimation of NAFLD or NASH. The 
biochemical changes following LSG hold little merit without liver biopsy or 
diagnostic imaging to support the findings. The FLI and the SI were proposed as a 
first-step before assessment by ultrasound or liver biopsy, as they are more accurate 
than the biochemical parameters alone. Based on the calculations of the indexes, 100 
% of patients in the current study presented with a FLI > 60, ruling in fatty liver 
disease (either fatty liver disease or NAFLD). This proportion of patients is close to 
the proposed prevalence rate of 95 % as suggested by Feijo et al. (2013) and the 
prevalence ranging from 85 – 95 % as suggested by Machado et al. (2006). This, 
along with the 80 % of patients in the current study presenting with abnormal 
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values for the biochemical parameters, provides further support that NAFLD is 
underdiagnosed.  
Although significant improvements were observed for the mean SI values 
post-LSG, the lack of pre-determined cut-offs makes it impossible to determine the 
proportion of patients with or without NAFLD. The SI needs to be externally 
validated and cut-offs needs to be determined, before it can be used clinically. To 
fully establish the accuracy and validity of both the FLI and SI, more studies needs to 
be conducted. In order to fully determine the effect of weight loss following LSG on 
the NAFLD in this study, an assessment of the changes in liver health according to 
ultrasound or liver biopsy would have been necessary. 
In summary, the actual prevalence of NAFLD among the study sample is most 
likely higher than the 2.1 % reported, due to the purported high prevalence of 
NAFLD among the obese population and the large proportion of patients with 
abnormal blood values (80 %) and a FLI > 60 (100 %). The overall improvement in 
liver enzymes and lipid profile is consistent with the findings observed in other 
studies. The significant improvements of the parameters associated with NAFLD 
observed in this study along with the significant improvements in FLI and SI, may be 
attributed to the significant weight loss and improved liver health. As hypothesized, 
significant improvements in the majority of the biochemical parameters associated 
with NAFLD, mainly for ALT, GGT, HDL and triglycerides, were observed following 
LSG. 
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6. Limitations, clinical relevance and recommendations 
This section will present the limitations of the current study, the clinical 
relevance of the findings along with recommendations for future research on the 
micronutrient status and NAFLD in patients undergoing LSG. 
 
6.1. Study limitations 
With a recruitment rate of 99.5 % the possibility of selection bias is limited, 
indicating a study sample representative of the population of individuals seeking the 
LSG procedure in Newfoundland & Labrador. The longitudinal prospective cohort 
design was appropriate in order to detect any abnormalities for micronutrients or 
related parameters and assess the status of liver parameters at baseline, and to 
evaluate these abnormalities and parameters at 3 and 6 months following LSG.  
A possible limitation is the fact, that out of the 188 patients enrolled in the 
study, only 95 patients had completed their 3 and 6 months follow-up thus far. 
However, there is no indication that this subgroup of 95 patients were significantly 
different than the entire study population, thus the study findings are sufficiently 
generalizable. Still, this project is part of an ongoing study, therefore the sample size 
at each time-point is expected to increase as time progresses. The study is based on 
a pretest-posttest design without a control group, which could pose a limitation to 
the findings. Patients serve as their own controls, but because there is no 
independent control group, it is not possible to determine if the changes observed 
following LSG are in fact due to the LSG procedure itself.  
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A major limitation of this study, was the inability to determine the doses of 
vitamin D in the diverse number of supplements used by patients. Only the doses for 
vitamin D supplements were obtainable, but the majority of patients were taking 
vitamin D, a multivitamin (which likely contain vitamin D), a calcium supplement 
that may or may not also contain vitamin D, or an over-the-counter supplement. The 
total vitamin D consumption is unknown and therefore it is difficult to assess the 
impact of vitamin D consumption on the changes observed in 25-OH-D. The lack of 
statistical significance from the multivariate GEE analysis may have been attributed 
to the inability to analyze dose-response relationship and/or that too few patients 
were not taking a supplement in the follow-up period.  
Future studies assessing 25-OH-D levels post-bariatric surgery should aim to 
determine the doses of any supplement at each follow-up along with the dietary 
history and sunlight exposure. The findings on 25-OH-D and PTH need to be 
interpreted with caution, as the missing data could potentially underestimate the 
actual outcome. This concern will be addressed in the ongoing study.   
 
The baseline measurements for the micronutrient and related parameters 
were done after the initial orientation session, when patients were advised on 
healthy and nutritious diets and supplements. This could be a confounder and as 
such, the current baseline values might not provide the most accurate picture of the 
state of the patients receiving LSG, as they might have made changes to their diet 
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and supplement regimen before presenting for surgery. In addition, not all of the 
select micronutrient and related parameters measured in this study were examined 
in other studies identified on this topic of research. This limits the number of studies 
to draw comparisons with, thus making it difficult to draw any firm conclusions. In 
addition, some of the published studies are reporting findings for vitamin D and 
unless otherwise stated, an assumption was made that is was 25-OH-D, so it could be 
used for comparison.  
 
The blood concentrations of several of the biochemical parameters can be 
affected by diet. Patients in the study were advised of proper diet before and after 
undergoing LSG, which could have had an impact on the blood values. However, 
without a proper dietary history or assessments of intake (diet and supplements), 
the impact on the results presented remains unknown. The issues that arose with 
the PTH laboratory assay may have contributed to a false increase in elevated PTH 
prevalence. In addition, the assay used by the province for its 25-OH-D analysis 
differs from the radioimmunoassays (RIA) used in most other laboratories. This in-
house developed procedure is thought to report slightly higher blood values than 
what would have been reported by RIAs, whereas the RIAs tend to underestimate 
the true values of 25-OH-D. This could explain the low prevalence rate for 25-OH-D 
abnormalities observed in this study. 
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As all co-morbidities are self-reported, the number of co-morbidities 
reported is most likely biased. An example of this is the large proportion of patients 
with abnormal liver markers at baseline, but only three patients reporting a NAFLD 
diagnosis. The prevalence of co-morbidities reported is most likely conservative and 
underestimates the actual picture.  
 
6.2. Clinical relevance  
Micronutrient deficiencies and toxicities can only be determined if both the 
biochemical and the corresponding clinical symptoms are present in patients. Since 
this study is based solely on the biochemical findings, we are only examining the 
biochemical abnormalities, not deficiencies or toxicities. The mean values found in 
this study all remain within the normal references at baseline and post-operatively 
for the vast majority of the measured parameters. If the larger cohort confirms these 
data when all patients have completed their 24 months follow-up, and by other 
independent studies, it could suggest that LSG does not have an adverse effect on 
these biochemical parameters for the majority of patients. 
The diagnosis or staging of NAFLD and NASH are usually based on the 
findings from a liver biopsy or diagnostic imaging, not by the biochemical liver 
markers alone. However, liver enzymes and other liver parameters are often used as 
a helpful tool when combined with biopsy and imaging, such as ultrasound. The 
improvement of parameters associated with NAFLD in this study could possibly 
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indicate an improvement in overall liver health as well, but this would have to have 
been confirmed by the liver biopsy. The results from this study could be used in 
clinical practise, if future studies can confirm the relationship between liver 
improvement and liver marker improvement.  
 
6.3. Recommendations for future research 
Future research in this area is important in order to fully understand the 
consequences of bariatric surgery on patients’ micronutrient and related 
parameters. This is important not only for the LSG procedure, but long-term studies 
for all bariatric surgery procedures, as there continues to be discrepancies on the 
changes in micronutrient and related parameters post-operatively. More 
longitudinal studies or randomized controlled trials should be conducted in order to 
determine the status in patients undergoing this procedure prior to and post-
surgery. As these abnormalities can be present prior to surgery, assessments should 
be made at this time, and any abnormality should be treated accordingly. An 
assessment should also be performed at several time-points post-LSG, to diagnose 





In addition, in order to fully assess the true impact of supplement use on 
changes in 25-OH-D blood levels post-LSG, the intake of vitamin D supplements 
needs to be quantified. Without this, it will not be possible to determine the relative 
effects of supplements, weight loss, and seasonal variations on the post-surgery 25-
OH-D levels.  
 
Prospective studies or a randomized controlled study aimed at the outcomes 
for NAFLD and NASH following LSG is greatly needed. It should be conducted with 
the use of diagnostic imaging, biochemical markers and possibly liver biopsies, all 
performed pre- or during surgery as well as at one or more follow-up time points. 
Overtime, this existing cohort of surgical patients will both grow in number and 
length of follow-up, adding clinically rich data that will help answer questions 







A significant improvement in 25-OH-D was observed following LSG, but it 
remains uncertain whether this improvement was due to the LSG itself or the 
increased use of vitamin D-containing supplements. The status of calcium, ferritin, 
hemoglobin and MCV did not change significantly following LSG. Although there was 
an initial increase in the proportion of patients with elevated PTH levels, this may 
have been attributed to technical issues at the Health Sciences Centre. A significant 
inverse correlation between absolute weight and 25-OH-D was demonstrated both 
prior to- and following surgery, along with a significant inverse correlation between 
weight loss and the increase in 25-OH-D levels from baseline to the 3-month follow-
up.  
 
Significant improvements were observed for the majority of the biochemical 
parameters associated with NAFLD, with a decreasing proportion of patients with 
abnormal blood levels for ALT, GGT, HDL and triglycerides observed post-surgery. 
Significant inverse correlations were observed for body weight and mean HDL blood 
levels at all three assessments (baseline, 3 and 6 months), along with a weak 




A significant improvement in the proportion of patients with a Fatty Liver 
Index > 60 was observed in post-operatively, along with significant improvements in 
the Steatosis Index. The improvements in the biochemical parameters associated 
with NALFD in addition to the improvements observed for both the Fatty Liver 
Index and the Steatosis Index, may be attributed to the significant weight loss 
observed post-operatively. 
The weight loss achieved by LSG may have beneficial impacts on the 
biochemical parameters associated with micronutrient status and non-alcoholic 
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Appendix 4.1. Laboratory changes of the biochemical parameters 
 
Laboratory values for bone health parameters at each time-point. 
 Normal reference Baseline 3 months 6 months 
25-OH-D 50-250 nmol/L (a) 69.6 ± 24.7 (94) 
(b) 24 - 156 
(a) 78.4 ± 23.9 (79) * 
(b) 35 – 160  
(a) 81.1 ± 23.8 (69) *  
(b) 40 – 148  
Calcium 2.12-2.62 mmol/L (a) 2.44 ± 0.10 (93) 
(b) 2.2 – 2.8  
(a) 2.43 ± 0.09 (93) 
(b) 2.2 – 2.7  
(a) 2.46 ± 0.11 (88) † 
(b) 2.2 – 2.8  
PTH 12-72 ng/L (a) 62.9 ± 35.0 (93) 
(b) 11 – 256  
(a) 74.1 ± 37.9 (89) * 
(b) 23 - 259 
(a) 70.9 ± 30.2 (87) *  
(b) 33 - 201 
Note: Repeated ANOVA/Friedman’s with Wilcoxon’s or GEE for variables with significant missing data points. (a) Mean +/- SD 







Laboratory values for hematological parameters at each time-point. 
 
 Normal reference Baseline 3 months 6 months 
Ferritin Male: 24.0 –  
336 μg/L 
(a) 250.6 ± 206.6 (17) 
(b) 63 – 832  
(a) 182.9 ± 128.2 (17) * 
(b) 55 – 493.9  
(a) 136.2 ± 65.0 (17) *† 
(b) 37.8 – 366.7  
 Female: 11.0 –  
307 μg/L 
(a) 130.2 ± 137.1 (78) 
(b) 6 – 947  
(a) 110.9 ± 96.6 (71) * 
(b) 6 – 561  
(a) 99.4 ± 97.4 (73) *† 
(b) 4 – 517  
Hemoglobin Male: 140 –  
180 G/L 
(a) 145.5 ± 12.8 (17) 
(b) 114 – 167  
(a) 144.3 ± 11.8 (17) 
(b) 117 – 162  
(a) 144.8 ± 12.2 (16) 
(b) 114 – 159  
 Female: 120 –  
160 G/L 
(a) 136.9 ± 11.2 (78) 
(b) 105 – 163  
(a) 136.4 ± 12.6 (76) 
(b) 98 – 177  
(a) 134.8 ± 12.2 (75) 
(b) 86 – 171  
MCV Male: 80 –  
97 fL 
(a) 89.8 ± 2.7 (17) 
(b) 85.9 – 94.4  
(a) 89.6 ± 2.9 (17) 
(b) 86.0 – 95.0  
(a) 91.1 ± 2.9 (16) *† 
(b) 85.2 – 97.7  
 Female: 81 –  
99 fL 
(a) 88.4 ± 4.9 (78) 
(b) 75.8 – 100.0  
(a) 88.9 ± 5.2 (76) 
(b) 69.9 – 101.7  
(a) 89.1 ± 5.6 (75) * 
(b) 67.0 – 101.7  
Vitamin B12 107 –  
675 pmol/L 
(a) 359.9 ± 159.1 (95) 
(b) 157 – 1016  
(a) 366.4 ± 178.3 (87) 
(b) 140 – 1332  
(a) 324.9 ± 178.3 (90) † 
(b) 118 - 854 
Note: Repeated ANOVA/Friedman’s with Wilcoxon’s. (a) Mean +/- SD (n). (b) Range (min – max). M: Males, F: Females. * p-





Laboratory values for parameters associated with NAFLD at each time-point. 
 
 Normal reference Baseline 3 months 6 months 
Bilirubin < 20 μmol/L (a) 12.2 ± 5.1 (93) 
(b) 5 - 36 
(a) 12.3 ± 5.2 (94) 
(b) 2.1 – 39.0 
(a) 13.2 ± 6.2 (92) * 
(b) 5 - 48 
ALP 40 – 150 U/L (a) 85.7 ± 22.5 (93) 
(b) 36 - 145 
(a) 82.2 ± 22.1 (92) 
(b) 38 - 144 
(a) 82.5 ± 20.3 (91) 
(b) 32 - 144 
ALT < 55 U/L (a) 31.5 ± 17.9 (93) 
(b) 9 - 111 
(a) 26.0 ± 15.1 (92) * 
(b) 7 - 97 
(a) 18.1 ± 7.5 (90) *† 
(b) 7 - 38 
GGT < 32 U/L (a) 36.2 ± 22.8 (93) 
(b) 10 – 177 
(a) 23.9 ± 13.9 (89) * 
(b) 6 – 100 
(a) 21.4 ± 16.3 (84) *† 
(b) 5 – 136 
HDL > 0.9 mmol/L (a) 1.04 ± 0.22 (94) 
(b) 0.52 – 1.69  
(a) 1.02 ± 0.18 (93) 
(b) 0.64 – 1.49  
(a) 1.12 ± 0.22 (92) *† 
(b) 0.76 – 1.81  
LDL < 3.4 mmol/L (a) 2.85 ± 0.98 (92) 
(b) 1.03 – 5.12 
(a) 2.61 ± 0.90 (93) * 
(b) 0.92 – 5.55 
(a) 2.79 ± 0.88 (92) † 
(b) 0.66 – 5.33 
Triglycerides < 1.9 mmol/L (a) 1.98 ± 0.92 (94) 
(b) 0.83 – 6.17  
(a) 1.42 ± 0.44 (93) * 
(b) 0.63 – 3.02  
(a) 1.33 ± 0.48 (92) *† 
(b) 0.54 – 3.52  
Note: Repeated ANOVA/Friedman’s with Wilcoxon’s. (a) Mean +/- SD (n). (b) Range (min – max). M: Males, F: Females. * p-
value < 0.05 when compared to baseline, † p-value < 0.05 when compared to 3 months.  
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Appendix 4.2. Univariate and multivariate generalized estimating equation models 
 
25-OH-D and Time: 
Test of Model Effects 
 
Source 
Type I Type III 
Wald Chi-
Square 

















Dependent Variable: Vitamin D 

















95 % Wald Confidence 
Interval 
Hypothesis Test 






































Dependent Variable: Vitamin D 









25-OH-D and Seasons: 
 
Season 1. Winter: December 21st – March 19th  
Season 2. Spring: March 20th – June 20th  
Season 3. Summer: June 21st – September 21st  
Season 4. Fall: September 22nd – December 20th  
 
Test of Model Effects 
 
Source 
Type I Type III 
Wald Chi-
Square 

















Dependent Variable: Vitamin D 













95 % Wald Confidence 
Interval 
Hypothesis Test 




[Seasons = 4] 
[Seasons = 3] 
[Seasons = 2] 






































Dependent Variable: Vitamin D 
Model: (Intercept), Seasons 





25-OH-D and Overall Supplement use: 
 
Test of Model Effects 
 
Source 
Type I Type III 
Wald Chi-
Square 

























Dependent Variable: Vitamin D 













95 % Wald Confidence 
Interval 
Hypothesis Test 



































Dependent Variable: Vitamin D 
Model: (Intercept), OSU = Overall Supplement Use. 1 = Yes, 0 = No 






25-OH-D, Time and Overall Supplement use: 
 
Test of Model Effects 
 
Source 
Type I Type III 
Wald Chi-
Square 






























Dependent Variable: Vitamin D 












95 % Wald Confidence 
Interval 
Hypothesis Test 







[OSU = 1] 



















































Dependent Variable: Vitamin D 
Model: (Intercept), Time and OSU = Overall Supplement Use. 1 = Yes, 0 = No.  
a. Set to zero as this parameter is redundant.
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Appendix 4.3. Scatterplot and correlation analysis for the Fatty Liver Index and the Steatosis Index 
 
 Baseline 3 months 6 months 
r 0.611 0.750 0.851 
p-value 0.000 0.000 0.000 
Type of correlation Moderate, Positive Strong, Positive Strong, Positive 
 
 
 
 
 
 
 
 
183  
Baseline 
 
 
 
184  
3 months 
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6 months 
 
 
 
